Elucidating the regulation of adenylyl cyclase type 9 by dynamic membrane trafficking by Lazar, Andre Mingyuen
UCSF
UC San Francisco Electronic Theses and Dissertations
Title
Elucidating the regulation of adenylyl cyclase type 9 by dynamic membrane trafficking
Permalink
https://escholarship.org/uc/item/7p6979fv
Author
Lazar, Andre Mingyuen
Publication Date
2019
 
Peer reviewed|Thesis/dissertation
eScholarship.org Powered by the California Digital Library
University of California
  
 
 
 
by 
 
 
 
 
Submitted in partial satisfaction of the requirements for degree of 
 
 
in 
 
 
 
in the 
 
GRADUATE DIVISION 
of the 
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO 
 
 
 
 
 
 
 
 
 
 
 
 
Approved: 
 
______________________________________________________________________________ 
       Chair 
 
 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
Committee Members 
Cell Biology
DOCTOR OF PHILOSOPHY
André M. Lazar
DISSERTATION
Elucidating the regulation of adenylyl cyclase type 9 by dynamic membrane trafficking
Mark von Zastrow
Dyche Mullins
Jack Taunton
ii 
 
  
iii 
 
Dedication and Acknowledgements 
I am incredibly grateful for all the people who have helped me throughout my graduate 
career. Naturally the person who most influenced my experience in graduate school 
was my PI, Mark von Zastrow. Mark is the kind of scientist who is in basic research for 
the right reasons. His boundless energy and enthusiasm are infectious, and his 
willingness to pursue the hardest questions is what separates him from his peers. As a 
mentor, Mark has the rare ability to find the balance of guidance and freedom that each 
student needs to flourish. He is able to maintain a rigorous work ethic while not taking 
himself too seriously, which is something I hope to achieve one day.  
 
I will forever be thankful for the help and support I received from other members of the 
von Zastrow lab, both past and present. First and foremost, I must thank Roshanak 
Irannejad, who mentored me throughout my first few years in the lab. Roshanak is a 
fantastic role model who is always reading and learning. She demonstrates and expects 
technical excellence in experimentation, and I would not be half the scientist I am today 
without her. Roshanak is a true joy to learn from and collaborate, and she has a big 
heart and a life full of fascinating stories. It is hard to imagine anyone more deserving of 
success and I am incredibly proud of her. She’s started her own lab at UCSF and I 
could not recommend her more highly to incoming students.  
 
The next person I must thank may surprise her, but Nina Tsvetanova was someone who 
always believed in the validity of my data and the importance of my project. She has 
high expectations for herself and others, and is a great person to have in your corner. 
iv 
 
Braden Lobingier is a devoted scientist whose detail oriented nature makes him the 
consummate academic. He was always willing to help me troubleshoot my experiments; 
as the ‘Reviewer #2’ of the lab, his creativity for experimental controls is matched only 
by his impressive knowledge of several fields of literature. Miriam Stoeber is an 
incredibly talented scientist, and the depths of her empathy and social graces make her 
a standout amongst the scientific community. Damien Julie is a multi-talented 
experimentalist with creative approaches that proved invaluable for tackling the hardest 
problems. Yasunori Uchida is a great friend whose steady presence and quick laugh 
helped me through many difficult days. Thanks also to Erica Sanchez for being a ray of 
sunshine blasting through the clouds of cynicism in my last months of graduate school, 
Lea Ripoll for her chill vibes, and Aliza Ehrlich for her infectious smile. 
 
Thanks also to Dyche Mullins, Jack Taunton and Henry Bourne for their valuable 
insights as my thesis advisors and mentors. Dyche is full of good cheer, and impressed 
me every time we spoke with his well rounded, comprehensive perspectives and 
absolute rigor in experimental design. He supported and encouraged me while also 
holding me to a high standard, and I am grateful for that balance and glad he was on my 
committee. Jack is one of the smartest people I’ve ever met and constantly pushed me 
to be my best. I knew I needed him on my committee for two reasons: his incisive 
criticism and his willingness to be fully engaged with my project. Henry, our resident the 
professor emeritus and unofficial UCSF historian shared with me his quick wit, 
outrageous stories, and scientific perspectives. His energy, good humor and 
enthusiasm made me feel included in the UCSF community. 
 
v 
 
My fellow graduate students, both inside and outside the von Zastrow lab, were 
constant and true companions. Alison Leaf took me under her wing before I even joined 
the lab. Her unique combination of ebullience and direct, in your face approach made 
her a joy to be around. Kate Varandas is one of the most empathetic people I know and 
I thank her for her kindness. Kelsie Eichel is a brilliant scientist and her sense of humor 
cracked me up many times throughout the years. Grace Peng and I joined the von 
Zastrow lab together and she had my back the whole time. Grace is a great labmate 
and a better friend to those lucky enough to call her one. Ben Barse-Rhyne is always 
willing to share his time, his opinion, and his good vibes, and I’m grateful for all of them. 
Joy Li is a kind and loving person who is always thinking of others first.  
 
Thanks also to my fellow Tetrad classmates Candace Britton, Fernando Meza 
Gutierrez, Johnny Rodriguez, Joel Hrit, and Kelly Crotty. Together we made the first 
couple years of graduate school a blast and were able to help and support each other 
through the good times and bad. Candace and I share the exact same sense of humor 
and pop culture tastes, and our friendship was born out of our passion for the skits we 
made in our second year. I lived with Fernando, Johnny, and Joel for a year and it was 
awesome to be part of the Hufflepuff House even though I’m obviously a Gryffindor. 
Thank you Kelly for your good cheer, patience, and expansive movie knowledge. I will 
always remember and be thankful for all the fun times we all shared.  
 
None of this would be possible without the help and support of my family. My parents, 
Aurel and Paik-kee, have always helped me construct and pursue my goals, cheered 
me on, and pushed me to do my best. Papa has always been a willing sounding board; 
vi 
 
sometimes I wondered if he was more interested in my project than I was! He is a 
dedicated intellectual and I’ve learned the joys of puzzle solving from him. Mama has 
always fought to make sure I am a well-rounded person who has a life outside of work 
and interests in the world around me. She instilled in my sister and I the value of family 
and taught us how to treat our fellow human beings. Thank you both for always having 
faith that I would figure things out, even when I wasn’t so sure I could. Thanks also to 
my little sister Katja, from whose personal journey I have learned so much about my 
own. Thank you Katja for always having my back, for all the times you called me to 
catch up, and for unabashedly being your true self. Thanks for being a great sister and 
a better friend. I’m proud to be your older brother and to help you through medical 
school as much as you helped me through graduate school.  
 
While my immediate family was in New York, my aunt Paik-Swan, my uncle Steve, and 
my cousins Audrey and Lauren were here in San Francisco. They were the reason I 
chose to come to UCSF and I’m really glad I did. My aunt and uncle are some of the 
warmest, most generous people I’ve met and I genuinely looked forward to going to 
their house for dinner every week or so. They were always around when I needed them, 
and were my home away from home for seven years. I watched Audrey grow up 
through middle and high school, tackling tons of challenges along the way. I couldn’t be 
more proud of the elegant young lady she has become, and I am glad to have been a 
part of her life during these important years. Lauren has always been as much a sister 
as a cousin, and growing up with her has been a pleasure. Her distinctive laughter is 
infectious, and her moral clarity and raw intellect are reassuring in a political 
environment which seems devoid of such necessary and valuable traits.  
vii 
 
 
While I have family on both the east and west coasts on whom I can rely, I also gained 
a new family. I met Haley Rose Smith in the summer of my second year of graduate 
school and quickly fell head over heels for her. Haley has the biggest heart of anyone 
I’ve ever met, and truly and deeply cares for others. She has taught me so much about 
the rapidly changing world outside of academia, and I am forever grateful to have been 
so quickly welcomed into her family, including Dave, Denise, Campbell and the whole 
Smith and White clans. I’ve always told her that I’ll never quite have the words to fully 
describe how much I love her, but here are a few: Haley, you are a shining light in a 
dark world, my best friend, and an astoundingly loving and devoted partner. If I am the 
rock that holds you steady, you are the wind that lifts me up and carries me to new 
heights. It is to you that I dedicate this thesis, as without you I never would have come 
this far.  
 
  
viii 
 
Abstract 
Elucidating the regulation of adenylyl cyclase type 9 by dynamic membrane trafficking 
by  
André M. Lazar 
This dissertation delves into the regulatory mechanisms that govern the dynamic 
redistribution of adenylyl cyclase type 9 (AC9) from the plasma membrane to the early 
endosome. Adenylyl cyclases (ACs) are 12-transmembrane proteins that catalyze ATP 
to the second messenger molecule, cyclic AMP. ACs are critical effectors of G protein 
activation, and AC9 is the first AC isoform described at the endosome. The introduction 
provides a general overview of the relationship between G protein coupled receptor 
(GPCR) mediated signaling and membrane trafficking. It also describes the evidence 
supporting GPCR-mediated signaling from the endosome, the importance of local cAMP 
signaling, and regulatory mechanisms that govern adenylyl cyclase isoforms. The 
second chapter explores the regulated endocytosis of AC9 and its contribution to a 
B2AR-mediated cAMP response from the endosome. We show that AC9 internalization 
is a result of Gs-coupled receptor activation, but more specifically that Gs activation is 
necessary and sufficient for this process. The third chapter describes the 
troubleshooting of the cell culture and fixation protocol, and ultimately determines that 
AC9 trafficking is sensitive to acute exposure to a negative CO2 gradient. The fourth 
chapter is a discussion of these findings, future directions and implications on the field. 
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Chapter 1: 
 
Introduction 
  
1 
1.1 Overview 
 
This thesis focuses on the Adenylyl Cyclase type 9 (AC9), one of the nine isoforms of 
transmembrane adenylyl cyclases that are expressed in mammals. Adenylyl cyclases 
are critical effector proteins that amplify a signal that is initially detected by a G protein 
Coupled Receptor (GPCR). As such, the regulation of adenylyl cyclase activity is often a 
pivotal step in several cellular responses. The introduction chapter provides a general 
overview of the current model of the GPCR, G protein, and adenylyl cyclase signaling 
cascade, and how this relates to membrane trafficking within endocytic network. It aims 
to provide the proper context for the present understanding of receptor mediated 
signaling from various locations in the cell, as well as to present the outstanding 
questions in the field regarding the action of effector molecules from these locations.  
 
 
 
 
 
 
 
 
  
2 
1.2 Early exploration of GPCR signaling and membrane trafficking 
G-protein coupled receptors constitute the largest family of signaling receptors and 
integral membrane proteins in mammals ​(Holst and Schwartz 2002)​. GPCRs are a 
major focus of pharmaceutical drug targets, with an estimated one-third of all drugs in 
clinical use targeting GPCRs ​(Hauser et al. 2017)​. These receptors are 
seven-transmembrane proteins that are inserted into the endoplasmic reticulum 
membrane during translation. They undergo post-translational modifications at the 
endoplasmic reticulum and Golgi apparatus including glycosylation, which is necessary 
for structural integrity and downstream signaling. GPCRs are so-named because many 
of their downstream signaling effects are transduced by heterotrimeric GTP-binding 
proteins (G proteins) to effector proteins ​(Weis and Kobilka 2018)​. Ligand binding 
results in stabilization of the receptor in a conformation that promotes allosteric coupling 
to the G protein ​(Weis and Kobilka 2018)​. This receptor-G protein coupling results in 
nucleotide exchange from GDP to GTP by the G protein, commonly termed as 
activating the G protein, allowing it to engage downstream effectors, thus propagating 
the signal ​(Hepler and Gilman 1992; Hilger, Masureel, and Kobilka 2018)​.  
 
Early evidence that GPCR signaling undergoes regulation by membrane trafficking was 
discovered using the beta-2 adrenergic receptor (B2AR) as a model. These receptors 
recognize epinephrine in the bloodstream and are pivotal in mammalian adrenal 
response. B2ARs couple to the stimulatory G protein (Gs), which promotes adenylyl 
cyclase (AC) activity ​(Busto et al. 2000)​. The B2AR-Gs-AC signaling cascade was used 
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to demonstrate a desensitization effect in which larger doses were required to stimulate 
the same scale response, as measured by elevated cyclic adenosine monophosphate 
(cAMP) levels in the cell ​(Su, Harden, and Perkins 1979)​. Short term agonist exposure 
resulted in reversible reduction in cAMP production without a commensurate reduction 
in total number of receptors detected in whole cell lysates ​(Su, Harden, and Perkins 
1979)​. Prolonged agonist exposure resulted in downregulation of receptor number that 
required new protein synthesis to recover ​(Doss, Perkins, and Harden 1981)​.  
 
A nondestructive process of receptor ‘sequestration’ was detected by subcellular 
fractionation and radioligand-receptor binding assays ​(Alho et al. 1988; Chuang and 
Costa 1979; Staehelin and Simons 1982)​. This was initially described as a cycle in 
which agonist induced receptor redistribution from the plasma membrane fraction to the 
‘soluble’ (later defined as endosome) fraction ​(von Zastrow and Kobilka 1992; Waldo et 
al. 1983)​. This sequestration in the soluble fraction eventually reversed, and this 
iteration between the plasma membrane and endosomes was found to correlate with 
receptor phosphorylation by GPCR kinases (GRKs) ​(Benovic et al. 1989)​. Receptor 
phosphorylation was also shown to attenuate receptor-G protein coupling ​in vitro ​(Sibley 
et al. 1985)​, and as a result, a model in which ligand binding resulted in receptor 
phosphorylation and sequestration in the endosome limiting membrane was proposed 
(Gagnon, Kallal, and Benovic 1998)​. 
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Receptor phosphorylation was also found to promote interaction with arrestin (or 
beta-arrestin) proteins ​(Gagnon, Kallal, and Benovic 1998; Goodman et al. 1996)​. 
Arrestin was so-named because receptor engagement with arrestin correlated with a G 
protein-dependent signal arrest as detected by cellular cAMP levels ​(Ferguson et al. 
1996​; ​M. J. Lohse et al. 1990)​. Arrestin was demonstrated to be an endocytic adaptor 
protein that also bound to the clathrin lattice structure and PIP2, promoting the 
accumulation of B2ARs in clathrin coated pits (CCPs) ​(Gaidarov et al. 1999)​. 
Accumulation of receptors in CCPs was shown to be critical for endocytosis to the early 
endosome as well as for proteolytic downregulation in lysosomes. 
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1.3 An evolving view of the endosome 
B2ARs are a common model both in the field and in the von Zastrow lab. Due to the 
historical exploration of B2AR membrane trafficking and its G protein dependent 
signaling, much of this system is well defined, and numerous tools are available, making 
it an excellent model for basic research. These tools include pharmaceutical drugs and 
mutants that have a wide range of effects on both signaling and trafficking of the 
receptor, including both agonist and antagonist effects. These tools have helped define 
a general model for GPCR signaling and regulation by membrane trafficking.  
 
Central to the ‘traditional model’ of GPCR signaling and trafficking that was developed 
are these key points: 1. Ligand-induced activation of GPCRs and G proteins is initiated 
at the plasma membrane and 2. GPCR endocytosis is associated with events that 
reduce or terminate G protein activation. The commonly held belief for many years was 
thus that the plasma membrane was the locus of receptor-mediated signaling in the cell, 
and the endosome represented a pool of inactive receptors that were sequestered from 
further stimulation (desensitization). 
 
The endosome has since been described beyond a sequestration mechanism. 
Published works from the von Zastrow lab as well as several others have explored the 
role of the endosome as the unit of the endocytic network. Indeed, the endosome is now 
understood to represent a mobile site of cargo sorting, from which receptors can be 
delivered to the plasma membrane (recycling) ​(von Zastrow and Kobilka 1992)​, 
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lysosome (degradation) ​(Henry et al. 2011)​, and the endoplasmic reticulum or Golgi 
apparatus ​(Varandas, Irannejad, and von Zastrow 2016)​. The endosome has also been 
shown to be the site of rapid receptor dephosphorylation, and G protein independent 
signaling from the endosome. The early endosome is thus the locus of the dynamic 
regulation of active and inactive receptors that can be scaffolded into signaling 
complexes and sorted to new locations in the cell.  
 
In particular the discovery of the retromer complex and retromer tubule, where much of 
the cargo sorting decisions are made, has greatly expanded the understanding of 
receptor regulation by membrane trafficking ​(Lauffer et al. 2010; Temkin et al. 2011)​. 
Retromer binding motifs on GPCR tails allow them to gain entry into the retromer tubule 
(Lauffer et al. 2010)​, a cilia-like protuberance from the endosome that is defined by the 
retromer complex ring at its base and along its shaft that warps the lipid bilayer as well 
as selects cargo ​(Varandas, Irannejad, and von Zastrow 2016)​. This tubule will 
eventually undergo scission from the early endosome and can be targeted to specific 
locations in the cell, allowing for directed delivery based on cargo identity ​(Temkin et al. 
2017; Choy et al. 2014)​.  
 
In addition to cargo sorting, the endosome has now been described as the site for 
receptor-mediated signaling. As the early model described the arrest of G protein 
dependent signaling by phosphorylation, arrestin binding, and endocytosis, the initial 
focus on receptor signaling from the endosome was largely G protein independent. 
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Arrestin mediated signaling from the plasma membrane and endosome has been well 
described by several studies ​(Varandas, Irannejad, and von Zastrow 2016; Eichel, 
Jullié, and von Zastrow 2016; DeFea et al. 2000)​. Certain GPCRs have been 
characterized as remaining engaged with arrestins at the endosome well into the 
maturation of the endosome ​(Shenoy and Lefkowitz 2011)​. Indeed, certain Class B 
GPCRs have been described by the Lefkowitz lab as forming a Super Complex with 
arrestin and G protein ​(Thomsen et al. 2016)​. Whether this ‘megaplex’ is necessary for 
all ligand-induced, receptor-mediated G protein dependent signaling, remains unclear at 
this time.  
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1.4 Evidence supporting GPCR-mediated signaling at the endosome 
There is now substantial evidence that endosomes are also the site of 
receptor-mediated G protein dependent signaling. Several different approaches have 
been supportive of the idea that GPCRs can activate G protein dependent signal 
cascades at the endosome, but none have been definitive. The three general categories 
of approach can be defined by their targets: 1. Disruption of receptor-ligand binding 
(either by agonist washout or competition with permeable or impermeable antagonists), 
2. Inhibition of receptor trafficking (either by mutation or by inhibitor treatments), or 3. 
Detection of active-conformation receptor and G protein by conformation-specific 
single-chain antibodies (nanobodies).  
 
Disruption of ligand binding by washout revealed a persistent cellular cAMP response 
(Calebiro et al. 2009​; ​Ferrandon et al. 2009; Thomsen et al. 2016; Stoeber et al. 2018)​, 
and the comparison of membrane permeant and impermeant antagonists showed an 
incomplete effect by the impermeant antagonist (which is unable to rapidly access the 
endosome lumen) relative to the permeant antagonist ​(Thomsen et al. 2016; Stoeber et 
al. 2018)​. These suggested that GPCRS could mediate a cellular response 
post-endocytosis. In chapter 2, we use the comparison of permeant and impermeant 
antagonists as an approach to demonstrate B2AR-mediated signaling from the 
endosome. 
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Endocytic blockade of the B2AR was achieved in two main ways: genetic or chemical. 
Genetic manipulation included the mutation of key tail residues that are phosphorylated 
and thus necessary for arrestin binding, expression of a dominant-negative form of 
dynamin (necessary for scission of a clathrin coated pit from the plasma membrane), 
and knockdown of clathrin. Chemical manipulation included treatment with small 
molecule inhibitors that inhibit the activity of key proteins necessary for endocytosis 
(DYNGO-4a is used to block dynamin activity in this study), or use of agonists for the 
B2AR that induce a cAMP response via Gs but do not promote B2AR endocytosis. Both 
genetic and chemical blockade of receptor endocytosis showed that restriction of the 
receptor to the plasma membrane reduced the overall response rather than increasing it 
(Calebiro et al. 2009; Ferrandon et al. 2009; Lyga et al. 2016; Irannejad et al. 2013)​. 
This was consistent with the idea that there is a cellular response originating at the 
endosome as well as the plasma membrane.  
 
Finally, the most recent evidence that GPCRs can mediate a signal that is transduced 
by G protein at the endosome used nanobody biosensors. These single-chain 
antibodies, cloned into an EGFP vector, were used to demonstrate that B2ARs could 
respond to a membrane permeant agonist isoproterenol both at the plasma membrane 
and the endosome ​(Irannejad et al. 2013)​. Typically dispersed throughout the 
cytoplasm, agonist stimulation of the B2AR resulted in the rapid recruitment of 
Nb80-EGFP, which recognizes the ‘active conformation’ of the receptor, to the plasma 
membrane, and then to the endosome ​(Irannejad et al. 2013)​. Further, Nb37-EGFP, 
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which preferentially binds to the nucleotide-free state of the Gs protein, was recruited to 
the endosome after treatment with isoproterenol ​(Irannejad et al. 2013)​. These data are 
consistent with the idea that there is ligand-receptor binding at the endosome and that 
this results in G protein activation. Similar strategies were used in the context of the 
Mu-Opioid Receptor ​(Stoeber et al. 2018)​ and Thyroid Stimulating Hormone Receptor 
(A et al. 2018) 
 
Proponents of endosome signaling favor a model in which the endosome functions to 
trap ligand within the lumen, raising or at least preserving the effective agonist 
concentration ​(Bowman, Shiwarski, and Puthenveedu 2016)​. This promotes ligand 
rebinding after dissociation from the receptor, consistent with the sustained response 
model. Additionally, GPCR-G protein activation at the endosome can preferentially 
promote a GPCR-dependent transcriptional response that is absent from cells in which 
GPCR-G protein activation occurs only at the plasma membrane ​(Tsvetanova and von 
Zastrow 2014; Calebiro et al. 2009; Jean-Alphonse et al. 2014)​.  
 
Detractors of endosome signaling point to the rapid diffusion that the small molecule 
cAMP exhibits in the cell. The source of the cAMP does not affect the structure of the 
molecule, so it can be difficult to see why an effector at another cellular location might 
differentiate between cAMP that originates from the plasma membrane or from the 
endosome. It remains unclear whether the rise in overall cAMP concentration in the cell 
is relevant to a cellular response, or if local generation of high-concentrations cAMP 
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(acute cAMP gradients) is of more importance. Scaffolding of signaling molecules is a 
common phenomenon in signal cascades, and it has been shown that enforced 
proximity enhances local signaling by cAMP ​(Agarwal, Clancy, and Harvey 2016; C. 
Lohse et al. 2017; Esseltine and Scott 2013)​. Local phosphodiesterase (PDE) activity 
can also create a low local cAMP concentration, potentially buffering against a rise in 
global cAMP levels nearby relevant effectors. 
 
 
  
12 
1.5 AKAPs confer spatial and effector specificity on cAMP signaling 
Spatial compartmentalization of cAMP-dependent signaling is accomplished in part by 
A-Kinase Anchoring Proteins (AKAPs) ​(Dessauer 2009)​. AKAPs perform a scaffolding 
function, coordinating several critical signaling molecules into close proximity ​(Gros et 
al. 2006)​. This typically includes Protein Kinase A, a primary effector of cAMP in many 
cell types, and phosphodiesterases (PDEs) which degrade cAMP, reducing local 
concentration ​(Davare 2001)​. AKAPs can also be involved in the scaffolding of GPCRs, 
G proteins, and ACs, and several effectors including calcium channels in neurons 
(Davare 2001)​. AKAPs can thus link individual signaling pathways through forced 
proximity, with clinical relevance. Of great importance is the fact that each AKAP only 
binds certain AC isoforms, and exhibit differential subcellular localization patterns.  
 
There is substantial evidence that the location of cAMP production is relevant for its 
downstream effects. Initiation of a cAMP response from the plasma membrane and a 
response from endosomes or cytoplasm have been demonstrated to have differential 
results ​(Tsvetanova and von Zastrow 2014)​. It is now clear that AKAPs and their 
preferential binding of different ACs and effectors is a mechanism for conferring 
specificity of outcome upon a universal signal in cAMP ​(Esseltine and Scott 2013)​. 
Local production of cAMP by ACs is necessarily more relevant to AKAP-bound effectors 
than not. Furthermore, PDE activity (coordinated by AKAPs) may function to either filter 
out ‘noise’ of a rise in cytoplasmic cAMP or even inhibit the spread of cAMP from 
AKAP-bound ACs ​(Smith et al. 2006)​. Coordination of signaling cascades by AKAPs at 
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various locations in the cell represents a more dynamic model of GPCR-mediated 
signaling. Although there is a massive diversity in GPCRs, G proteins, downstream 
effectors, and even nine AC isoforms, cAMP remains unchanged throughout a wide 
variety of signaling pathways. AKAPs are necessary for the recovery of input-output 
specificity after a receptor-mediated signal is transduced through a molecule that retains 
no inherent information. 
 
To our knowledge, only AKAP79/150 has been described in EEA1+ early endosomes 
so far. Palmitoylation of two conserved cysteine residues (C36 and C129) on the 
N-terminal tail of AKAP79/150 promotes association with lipid rafts and Rab11-positive 
endosomes in Cos7 cells and hippocampal neurons ​(Keith et al. 2012)​. This 
palmitoylation was also found to promote targeting of PKA and calcineurin to 
endosomes in these cells ​(Delint-Ramirez et al. 2015)​. Further, AKAP79/150 
palmitoylation is required for synaptic homeostasis and long term potentiation in 
hippocampal neurons ​(Keith et al. 2012)​. It is clear that targeting of this scaffolding 
protein to the endosome has large functional relevance, and strongly implicates the 
coordination of a cAMP response with local effectors at the endosome.  
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1.6 Adenylyl Cyclases  
The GPCR-G protein-Adenylyl Cyclase-cAMP signal cascade one of the most highly 
studied signal transduction pathways in mammals. Despite a great diversity of receptors 
and eventual downstream effects, cAMP responses always involve receptor and G 
protein coupling, and G protein regulation of adenylyl cyclase activity ​(Sunahara, 
Dessauer, and Gilman 1996)​. This basic structure has been described in a vast number 
of biological processes including (but not limited to): oogenesis, embryogenesis, larval 
development, hormone secretion, glycogen breakdown, smooth muscle relaxation, 
cardiac constriction, olfaction, and learning & memory ​(Sadana and Dessauer 2009)​. 
Insights into the structure and function of adenylyl cyclases have come from several 
fields, and basic research progress has an intimate connection with pharmaceutical 
drug development.  
 
Adenylyl cyclases are ATP-pyrophosphate lyase which converts ATP to cyclic AMP and 
pyrophosphate ​(Gilman 1989)​. Nine mammalian isoforms of transmembrane adenylyl 
cyclases have been defined, and a tenth ‘soluble’ form (sAC) has been recognized 
(Sadana and Dessauer 2009)​. All transmembrane ACs share a similar topology: two 
repeats of a 6-transmembrane anchor domain followed by a catalytic domain in the 
cytoplasm ​(Krupinski et al. 1989)​. The cytoplasmic domains (C1 and C2) are over 40% 
identical in both primary sequence and tertiary structure. C1 and C2 are highly 
conserved across isoforms, and interact with each other to create a pseudosymmetric 
site that can be regulated by different factors. C2 differs from C1 in that it binds the 
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stimulatory G protein (Gs), which promotes catalytic activity, while C1 can (depending 
on the isoform) bind the inhibitory G protein (Gi) ​(Taussig, Iniguez-Lluhi, and Gilman 
1993)​.  
 
All transmembrane AC isoforms are sensitive to Gs. There are four classes of AC 
isoforms that have been defined based on the regulatory mechanisms that they are 
sensitive to. Group 1 includes AC1, AC3, and AC8. These ACs are also stimulated as a 
result of elevated levels of Ca​2+​ through calmodulin ​(Choi, Xia, and Storm 1992)​. Group 
2 includes AC2, AC4, and AC6, all of which are stimulated by G​ γ​ but not by Gi ​(Tang 
and Gilman 1991)​. Group 3 constitutes AC5 and AC6, which are sensitive to both G​ γ 
and Gi, and are inhibited by an increase in free Ca​2+​ ​(Tang and Gilman 1991)​. Last but 
not least, Group 4 includes AC9 which is stimulated by Gs but not Gi, inhibited by 
calcineurin and Protein Kinase C, and is unique amongst AC isoforms in that it is 
relatively insensitive to forskolin (FSK), a diterpene molecule that promotes AC activity 
in a G protein independent manner in ACs 1-8 .  
 
AC isoforms are differentially expressed through mammals. AC1 is expressed in brain 
cells and in the adrenal medulla, and has been demonstrated to be involved in learning, 
memory, synaptic plasticity, and opiate withdrawal ​(Xia et al. 1993; Tzavara et al. 1996; 
Wu et al. 1995)​. AC2 is expressed in brain, lung, skeletal muscle, and heart tissues. 
AC3 is most associated with cilia and olfaction, and is found in the olfactory epithelium, 
pancreas, brain, heart, lung, and testes tissues ​(Z. Wang et al. 2006; Zou et al. 2007)​. 
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AC5 and AC6 are largely expressed in similar tissues, including heart, kidney, lunch, 
testis, and adrenal medulla ​(Espinasse et al. 1995)​. AC8 is expressed in brain, lung, 
pancreas, testis and adrenal medulla ​(H. Wang et al. 2003)​. AC4, AC7, and AC9 display 
widespread expression throughout cell types, and AC9 has been found to be involved in 
B2AR-mediated signaling in lung tissue and smooth muscle airway tissue more 
generally ​(Small et al. 2003)​.  
 
There are several studies that have suggested the involvement of specific AC isoforms 
in a cAMP response originating from endosome-localized GPCRs. Parathyroid 
Hormone Receptor (PTHR) has been shown to mediate a sustained signal from the 
endosome and has functional coupling with the B2AR ​(Ferrandon et al. 2009)​. PTHR 
appears to specifically activate AC2 post endocytosis, as demonstrated by selective 
inhibition of AC2, and overexpression of AC2 ​(Ferrandon et al. 2009)​. Soluble AC (sAC) 
has been implicated in the propagation of a cAMP signal that is endocytosis dependent. 
However, studies that identify subcellular localization of AC isoforms within the same 
cell type and across cell types are few and far between. This is partially hindered by the 
lack of highly specific antibodies that can differentiate between AC isoforms, and that 
endogenous expression of ACs is typically fairly low (limiting CRISPR-based tagging). 
As such, the subcellular localization of AC isoforms, and more specifically, whether they 
are present at the endosome, is poorly described.  
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1.7 Adenylyl Cyclase Type 9 
Adenylyl Cyclase Type 9 is widely expressed throughout cell types, including the central 
nervous system and heart ​(Berndt et al. 2013; Paterson et al. 1995)​. Knockdown 
studies have provided clear evidence that AC9 plays a role in neutrophil chemotaxis 
and cardiac function ​(Li et al. 2017)​. A polymorphism of the ADCY9 gene that encodes 
AC9 disrupts B2AR mediated signaling and is associated with risks for asthma, mood 
and body weight disorders ​(Small et al. 2003; Berndt et al. 2013)​. AC9 associates with 
the AKAP Yotiao and is coupled to I​Ks​ channel activity and cardiac repolarization ​(Li et 
al. 2012)​. Despite its clinical relevance, AC9 is perhaps the least studied of the AC 
isoforms and conflicting reports of its regulation have hindered progress in building a 
model for its function. 
 
AC9 is a Gs-regulated effector with several unique properties. AC9 is the most 
phylogenetically distant isoform and has been described to have an autoinhibitory 
domain in the C2b catalytic unit that is not shared amongst AC isoforms ​(Pálvölgyi et al. 
2018)​. Despite this autoinhibition, AC9 has also been described to have the highest 
basal activity amongst AC isoforms ​(Baldwin et al. 2019)​. AC9 was initially classified as 
the only Group 4 AC isoform, having been described as sensitive to inhibition by 
calmodulin and PKC, but not Gi or Gᵦᵧ ​(Dessauer et al. 2017)​.  
 
However, there are several conflicting reports of AC9 regulation, which may be 
explained by the discovery that AC9 can both homodimerize and heterodimerize with 
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AC5 and AC6 ​(Baldwin et al. 2019)​. The most recent study of AC9 regulation done ​in 
vitro​ found that AC9 is insensitive to direct inhibition by calmodulin, PKC, Gi and Gᵦᵧ 
(Baldwin et al. 2019)​. It remains possible that AC9 activity can be indirectly affected by 
these mechanisms ​in vivo​ through heterodimerization with other AC isoforms, likely with 
cell type specificity. All other AC isoforms are either stimulated (AC2, 4, 5, 6, 7) or 
inhibited (AC 1, 3, 8) by Gᵦᵧ through either direct or indirect means (sequestration of 
Gs), and it has been shown that Gᵦᵧ indirectly activates AC9 in neutrophils. PKC and 
calmodulin activity may need to be scaffolded (possibly by an AKAP) to facilitate 
phosphorylation of AC9, or may act on another protein which can regulate AC9 in cells. 
 
AC9 is also unique amongst AC isoforms in its relative insensitivity to the diterpene 
forskolin. Forskolin binds to all AC isoforms and stimulates cAMP production in a G 
protein independent manner ​(Qi et al. 2019)​. AC9 has been shown to bind FSK and 
even exhibit enhanced catalytic activity as a result, but this is contingent on 
engagement with Gs ​(Qi et al. 2019; Baldwin et al. 2019)​. Furthermore, AC9 has high 
basal activity relative to other ACs and requires a higher concentration of activated Gs 
to increase its catalytic activity ​(Baldwin et al. 2019)​. This high basal activity appears to 
be important for its physiological roles, particularly in cardiac function, as AC9 knockout 
in mice resulted in bradycardia and diastolic dysfunction ​(Li et al. 2017)​.  
 
AC isoforms have typically been assumed to be present at the plasma membrane for 
the bulk of their functionally relevant activity. Initial observations in other cells types 
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showed AC9 localization to the plasma membrane generally. AC9 is most typically 
associated with the AKAP Yotiao (encoded by the AKAP9 gene), which has been 
described as localized to the plasma membrane thus far ​(Li et al. 2012)​. However, AC9 
has been described at the Golgi apparatus in Cos7 cells, and was found to be 
necessary for trafficking of a GPCR-like receptor (KDELR) between the ER and Golgi 
(Cancino et al. 2014)​. In addition, a 2013 mass spectrometry study by the Cullen lab in 
which retromer components SNX27 and VPS35 were knockdown showed surface 
depletion of AC9 (amongst many other hits, but no other AC isoforms) ​(Steinberg et al. 
2013)​. This suggests that AC9 can both be present at the endosome and be sorted into 
recycling tubules by the retromer complex.  
 
In summary, the landscape of receptor-mediated cAMP signaling has evolved from a 
static model in which the plasma membrane is the locus of a massive cAMP gradient 
that rapidly diffuses to secondary targets in the cell. We now have a dynamic model 
which membrane trafficking can regulate receptor-mediated signaling from various 
locations in the cell with differential outcomes. A critical outstanding question is whether 
Gs regulated effectors are present in the endocytic network, and how they are 
coordinated into proximity with GPCR-G protein activation. This thesis focuses largely 
on adenylyl cyclase type 9 (AC9). We show that agonist engagement of the B2AR 
results in the redistribution of AC9 from the plasma membrane to the early endosome, 
and characterize this process as well as describe AC9 as a major contributor to the 
B2AR-mediated cAMP response from the endosome in HEK293 cells.  
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Chapter 2:  
Differentially regulated endocytosis of Adenylyl 
Cyclase type 9 contributes to the B2AR-mediated 
signaling from endosomes 
André M. Lazar conceived the project and performed all of the experiments and data 
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2.1 Abstract 
G protein-coupled receptors (GPCRs), the largest family of signal-transducing 
receptors, are increasingly recognized to activate cognate G proteins after 
ligand-induced endocytosis. A critical knowledge gap is whether relevant G 
protein-linked effectors exist in the endosome membrane. We show that adenylyl 
cyclase type 9 (AC9) is such an effector, and undergoes rapid redistribution from the 
plasma membrane to endosomes in response to activation of the Gs-coupled 
β2-adrenoceptor (β2AR). AC9 trafficking is isoform-specific because adenylyl cyclase 
type 1 (AC1) remains in the plasma membrane under similar conditions, and it is 
induced by activation of Gs- but not Gi-coupled GPCRs. AC9 can localize to 
endosomes independently from GPCRs and its trafficking requires Gs rather than 
beta-arrestin. Moreover, AC9 contributes to the β2AR-elicited cAMP response from 
endosomes. Taken together, these findings reveal the dynamic coordination by 
membrane trafficking of receptor-G protein activation with a functionally relevant 
G-protein linked effector within the endocytic network. 
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2.2 Introduction 
G-Protein Coupled Receptors (GPCRs) comprise the largest family of signaling 
receptors and an important class of therapeutic drug targets ​(Lefkowitz 2007)​. GPCRs 
are so-named because a major mechanism by which they mediate transmembrane 
signaling is through ligand-dependent activation of heterotrimeric G proteins that act as 
transducers of the intracellular signal ​(Spiegel 1987; Gilman 1987; Sunahara 1996)​. 
Canonical GPCR signaling cascades invariably require one additional component, an 
effector protein that is regulated by the G protein to convey the signal downstream 
(Dessauer, Posner, and Gilman 1996; Gilman 1987; Rosenbaum, Rasmussen, and 
Kobilka 2009)​. Such GPCR - G protein - effector cascades were thought for many years 
to operate exclusively in the plasma membrane, with the endocytic network considered 
only in the context of signal termination and proteolytic down-regulation of receptors 
(von Zastrow and Kobilka 1992; Sibley et al. 1986)​.  
 
The mechanism of receptor regulation by membrane trafficking has been well described 
for the beta-2 adrenoceptor (β2AR) ​(Sibley et al. 1986; Waldo et al. 1983; von Zastrow 
and Kobilka 1992)​, a member of the largest class (family A) of mammalian GPCRs that 
activates downstream signaling by coupling to the G stimulatory protein (Gs) ​(Lefkowitz 
2007)​. Phosphorylation of the receptor is required for arrestin binding ​(Lefkowitz 2007)​, 
which is critical for recruitment to clathrin-coated pits and dynamin-dependent 
endocytosis to the early endosome ​(Goodman et al. 1996)​. Arrestins have also been 
described to initiate G protein-independent downstream signaling cascades, including 
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from the endosome membrane, providing an early clue to the signaling potential of 
endosomes ​(Shukla, Xiao, and Lefkowitz 2011)​. There is an accumulating body of 
evidence for G protein-dependent signal initiation from endosomes ​(Irannejad et al. 
2013; Lyga et al. 2016; Kotowski et al. 2011; Ferrandon et al. 2009; Calebiro et al. 
2009; Vilardaga, Jean-Alphonse, and Gardella 2014; Lohse and Calebiro 2013; 
Irannejad et al. 2015; Stoeber et al. 2018; Thomsen et al. 2016; Slessareva et al. 2006)​. 
In mammalian cells, much of this evidence regards signaling via Gs, with 
ligand-dependent activation of both the β2AR and Gs explicitly demonstrated in 
endosomes ​(Irannejad et al. 2013)​.  
 
A major class of Gs-regulated effectors are the adenylyl cyclases (ACs) ​(Dessauer, 
Posner, and Gilman 1996; Sadana, Rachna, and Dessauer 2009)​. Gs-linked activation 
of adenylyl cyclase produces cAMP, a second messenger molecule which has several 
downstream targets including Protein Kinase A ​(Taylor et al. 2013)​. Mammals express 
nine AC isoforms, all of which are sensitive to Gs but differ both in their expression 
across cell types and sensitivity to regulation by other pathways ​(Sunahara 1996)​. While 
the regulation of adenylyl cyclase catalytic activity has been well described, relatively 
little is known about the subcellular distribution of AC isoforms or consequences thereof.  
 
G protein regulation of cAMP signaling requires GPCR, G protein and AC to be 
embedded in the same membrane bilayer ​(Gilman 1989)​. GPCRs and Gs are well 
known to undergo dynamic redistribution in the endocytic network ​(Irannejad et al. 2015; 
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Marrari et al. 2007)​ but much less is known about endocytic trafficking of ACs. Indeed, it 
has been generally assumed that GPCR-elicited cAMP production is restricted to the 
plasma membrane and relies on diffusion of cAMP for control of downstream targets. 
Nevertheless, adenylyl cyclase activity has long been recognized at internal membrane 
locations ​(Cheng and Farquhar 1976)​ and there is functional evidence that several AC 
isoforms contribute to endomembrane signaling ​(Ferrandon et al. 2009; Vilardaga, 
Jean-Alphonse, and Gardella 2014; Caldieri and Sigismund 2016; Cancino et al. 2014)​. 
However, to our knowledge, a specific AC isoform present in the endosome limiting 
membrane has not been identified, and dynamic regulation of ACs by membrane 
trafficking has remained largely undescribed. Here we demonstrate that β2AR-Gs 
activation triggers isoform-specific trafficking of adenylyl cyclase type 9 (AC9) and that 
AC9 mediates cAMP generation from endosomes.  
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2.3 Results 
β2AR activation promotes accumulation of AC9 but not AC1 in endosomes 
We chose an N-terminal Flag tagging strategy because AC1 function was previously 
shown to tolerate such a tag ​(Chen et al. 1997)​. In HEK293 cells, Flag-AC1 primarily 
localized at the plasma membrane (​Figure 2.1 (A)​), a distribution similar to that of an 
HA-tagged β2AR construct (HA-β2AR) in the absence of agonist (​Figure 2.1 (A)​). 
Application of the adrenergic agonist isoproterenol caused HA-β2AR redistribution to 
cytoplasmic punctae (​Figure 2.1 (A)​) that have been previously described as early 
endosomes ​(Irannejad et al. 2013; Temkin et al. 2011)​. In contrast, Flag-AC1 remained 
localized at the plasma membrane and did not visibly accumulate in these endosomes 
(​Figure 2.1 (A)​). We confirmed this observation across hundreds of cells captured by 
wide-field epifluorescence microscopy (​Figure 2.1 (M)​) and quantified the results in two 
ways. First, we determined the number of internal punctae per cell which were positive 
for HA-β2AR or Flag-AC1 (​Figure 2.1 (C)​). Second, we determined the fraction of cells 
visualized in each microscopic field that contained at least 10 such punctae (​Figure 2.1 
(D)​).  
 
We applied a similar tagging strategy to other AC isoforms and chose to focus on 
Flag-AC9 because it consistently expressed and localized to the PM similarly to 
Flag-AC1. We verified that Flag tagging also does not disrupt AC9 function (​Figure 2.1 
(K, L)​). In the absence of agonist, Flag-AC9 localized at the plasma membrane along 
with HA-β2AR (​Figure 2.1 (B)​). Within minutes after application of isoproterenol, 
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Flag-AC9 redistributed to internal punctae that colocalized with HA-β2AR (​Figure 2.1 
(B)​). Isoproterenol-induced accumulation of Flag-AC9 could be consistently observed in 
confocal optical sections (​Figure 2.1 (B)​) as well as by standard epifluorescence 
microscopy (sample data in ​Figure 2.1 (N)​ and​ ​quantified in ​(C, D)​). Live-cell confocal 
microscopy of HEK293 cells expressing AC9-EGFP confirmed these observations. 
 
Isoproterenol produced isoform-specific redistribution of AC9 in cells not expressing a 
recombinant β2AR construct (​Figure 2.1 (E, F, J)​) that was blocked by the 
beta-adrenergic antagonist alprenolol (​Figure 2.1 (G, H, J)​). This suggests that β2ARs 
expressed endogenously in HEK293 cells ​(Violin et al. 2008)​ are sufficient to drive AC 
trafficking and that this trafficking was not an off-target effect of isoproterenol. AC9 is 
endogenously expressed in HEK293 cells but at relatively low levels ​(Soto-Velasquez et 
al. 2018; Baldwin et al. 2019)​, and we were unable to detect endogenous AC9 in 
HEK293 cells using available antibodies. However, we did observe endogenous AC9 
immunoreactivity in primary human airway smooth muscle cells that express AC9 in 
relatively high abundance ​(Billington et al. 1999)​. Endogenous AC9 immunoreactivity 
was localized to the plasma membrane under basal conditions in these cells, and 
redistributed to internal punctae after application of isoproterenol (​Figure 2.1 (I)​).  
 
AC9 is internalized from the plasma membrane and accumulates in early endosomes 
Early Endosome Antigen 1 (EEA1) is a marker of early endosomes where 
ligand-dependent activation of both β2AR and Gs has been demonstrated ​(Irannejad et 
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al. 2013)​. Treatment with isoproterenol resulted in a colocalization of Flag-AC9 with 
EEA1 (​Figure 2.2 (A)​), while AC1 remained at the plasma membrane under similar 
conditions (​Figure 2.2 (B)​). We verified this isoform-specific accumulation in early 
endosomes using a vesicle immunoisolation procedure based on anti-EEA1 pulldown 
(Hammond et al. 2010; Temkin et al. 2011; Cottrell et al. 2009)​. Both HA-β2AR and 
Flag-AC9 accumulated in the endosome fraction as a result of isoproterenol treatment, 
as detected by immunoblot analysis (​Figure 2.2 (C, D)​). By contrast, isoproterenol 
produced endosomal accumulation of HA-β2AR, but not Flag-AC1, with both isolations 
carried out in parallel (​Figure 2.2 (C,​ ​D)​). Documenting the efficiency of separation and 
fraction purity, the immunoisolated fraction recovered ~34% of total cellular EEA1 but 
<​5% of Golgi, endoplasmic reticulum, or plasma membrane markers (​Figure 2.2 (G)​). 
 
As an additional biochemical verification, we used surface biotinylation to assess protein 
depletion from the plasma membrane ​(Flesch et al. 1995; Whistler and von Zastrow 
1998)​. Isoproterenol caused a pronounced depletion of Flag-AC9 but not Flag-AC1 from 
the surface-biotinylated fraction (​Figure 2.2 (E, F)​). Isoproterenol-induced depletion of 
HA-β2AR from the surface biotinylated fraction was observed in the same samples 
irrespective of the AC isoform coexpressed (​Figure 2.2 (E, F)​), with comparable loading 
confirmed in all experiments by immunoblot of lysate controls (​Figure 2.2 (E)​). These 
biochemical observations are consistent with the idea that AC9 undergoes depletion 
from the plasma membrane and accumulates in the early endosome fraction as a result 
of agonist stimulation of the β2AR.  
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 AC9 internalization is promoted by Gs- but not Gi -coupled GPCRs  
We next asked whether AC9 trafficking can be elicited by another Gs-coupled GPCR, 
focusing on the vasopressin-2 receptor (V2R) ​(Birnbaumer 2000)​. Unlike the β2AR, the 
V2R is not endogenously expressed in HEK293 cells. In cells expressing only Flag-AC9 
but not HA-V2R, the V2R agonist arginine-vasopressin (AVP) had no effect and 
Flag-AC9 remained in the plasma membrane (​Figure 2.3 (F)​). In contrast, in cells 
coexpressing HA-V2R, AVP caused Flag-AC9 redistributed from the plasma membrane 
to internal punctae (​Figure 2.3 (A, D, E, J)​). Surface biotinylation experiments 
confirmed that AVP produced a dramatic depletion of both HA-V2R and Flag-AC9 from 
the plasma membrane (​Figure 2.3 (H, I)​).  
 
We then investigated if AC9 trafficking to endosomes can be elicited by a Gi-coupled 
GPCR. To do so we focused on the µ-opioid receptor (MOR), a well characterized 
example ​(Kieffer and Evans 2009)​ not endogenously expressed in HEK293 cells. 
Agonist induced internalization of the MOR shares a similar mechanism with the β2AR, 
and MOR is delivered to β2AR-containing endosomes ​(Lauffer et al. 2010)​. Application 
of the µ-opioid agonist ​[D-Ala​2​, N-MePhe​4​, Gly-ol]-enkephalin (​DAMGO) resulted in 
robust accumulation of HA-MOR but not Flag-AC9 in endosomes (​Figure 2.3 (B, D, E, 
K)​), and we verified lack of AC9 internalization biochemically by surface biotinylation 
(​Figure 2.3 (H, I)​).  
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To begin to examine whether AC9 and GPCR trafficking are regulated by similar 
mechanisms, we focused on a previously described V2R mutant. This tail-truncation 
mutant retains its ability to activate Gs but lacks critical Ser/Thr residues in its 
cytoplasmic tail that are phosphorylated in response to AVP and promote V2R 
accumulation in early endosomes ​(Innamorati et al. 1997, 1998; Oakley et al. 1999)​. We 
confirmed that internalization of the truncated mutant receptor (HA-V2R-T) was 
detectably reduced relative to its wild type HA-V2R counterpart in the same cells 
(​Figure 2.3 (C, D, E, L)​). Despite this, AVP-induced activation of this truncated mutant 
receptor resulted in robust internalization of Flag-AC9 to internal punctae, as visualized 
by both confocal (​Figure 2.3 (C)​) and epifluorescence microscopy (​Figure​ ​2.3 (D, E, 
L)​). Surface biotinylation experiments verified that HA-V2R-T can mediate AVP-induced 
internalization of Flag-AC9 to a similar degree as the wild-type receptor (​Figure (H, I)​). 
Taken together, these results provide the first indication that AC9 trafficking correlates 
with receptor coupling to Gs, rather than with receptor tail phosphorylation and 
arrestin-dependent endocytosis.  
 
AC9 trafficking is not dependent on cytoplasmic cAMP or adenylyl cyclase activity 
We first considered the possibility that AC9 trafficking is a downstream consequence of 
elevated cytoplasmic cAMP concentration produced by Gs-coupled GPCR activation. 
To test this, we applied the diterpene drug forskolin (FSK) to directly activate adenylyl 
cyclases and thereby increase cytoplasmic cAMP concentration independently from 
receptor or Gs activation. Whereas AC9 is relatively insensitive to activation by FSK, 
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other AC isoforms that are major contributors to the cAMP production in HEK293 cells 
(particularly AC3 and AC6) are, making FSK an effective stimulus of overall cAMP 
elevation ​(Soto-Velasquez et al. 2018; Baldwin et al. 2019)​. FSK did not cause 
detectable internalization of HA-β2AR, and Flag-AC9 remained in the plasma 
membrane of FSK-treated cells (​Figure 2.4 (A, C, D, I)​), with FSK also failing to 
stimulate detectable internalization of either HA-β2AR or Flag-AC9 measured using 
surface biotinylation (​Figure 2.4 (E, F)​). Fully consistent with its lack of trafficking in 
response to receptor or Gs activation, Flag-AC1 remained in the plasma membrane 
(​Figure 2.4 (B, C, D, J)​) and did not detectably internalize in the presence of FSK 
(​Figure (E, F)​). Adding 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase 
inhibitor that further enhances the FSK-induced cytoplasmic cAMP elevation, also did 
not appreciably change the localization of HA-β2AR and Flag-AC9 (​Figure 2.4 (H)​).  
 
To determine whether enzymatic activity of AC9 is required for its internalization, we 
mutated a conserved aspartic acid residue​ ​in the active site, which coordinates a 
catalytic magnesium ion and was shown previously to be necessary for cAMP 
production by AC6 ​(Gao et al. 2011; Tesmer et al. 1997)​. Verifying that this mutation 
(AC9-D442A) also inactivates AC9, Flag-AC9-D442A overexpression did not detectably 
increase the cAMP response measured in HEK293 cells measured by whole cell cAMP 
assay, but wild type Flag-AC9 did (​Figure 2.1 (L)​). Despite significant loss of activity, 
Flag-AC9-D442A robustly internalized and colocalized in endosomes with HA-β2AR in 
response to isoproterenol-induced activation (​Figure 2.4 (G)​), indicating that the 
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adenylyl cyclase activity of AC9 is not necessary for regulated internalization of this AC 
isoform. 
 
Gs activation is sufficient to promote AC9 trafficking 
Since AC9 internalization can be promoted by Gs-coupled GPCRs but is insensitive to 
overall cytoplasmic cAMP elevation, we next determined whether activation of Gs itself 
is sufficient to promote AC9 internalization. To test this we used a point mutant of Gs 
(HA-Gs-Q227L) which has been previously described as constitutively active ​(Masters 
et al. 1989)​. Coexpressing Flag-AC9 with wild type HA-Gs resulted in localization of 
both proteins to the plasma membrane (​Figure 2.5 (A, C, D, K)​). In contrast, 
coexpression of Flag-AC9 with HA-Gs-Q227L resulted in the localization of both 
proteins to internal punctae (​Figure 2.5 (A, C, D, K)​). This effect was specific to AC9 
because AC1 remained localized to the plasma membrane when coexpressed with 
either HA-Gs or HA-Gs-Q227L (​Figure 2.5 (B, C, D, L)​). We verified by 
immunoisolation that both HA-Gs-Q227L and Flag-AC9 (​Figure 2.5 (G, H)​), but not 
Flag-AC1 (​Figure 2.5 (I, J)​), constitutively accumulate in EEA1-positive endosomes. 
Consistent with this finding, activation of endogenous Gs by ADP-ribosylation using 
cholera toxin (CTX) also produced receptor-independent internalization of Flag-AC9, 
while HA-β2AR and Flag-AC1 remained in the plasma membrane (​Figure 2.5 (M, N)​). 
 
We confirmed that isoproterenol treatment resulted in accumulation of HA-Gs and 
Flag-AC9 in the endosome fraction (​Figure 2.5 (E, F)​). However, in cells co-expressing 
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HA-Gs-Q227L, Flag-AC9 had already robustly accumulated in this fraction, and no 
additional effect was observed upon isoproterenol treatment (​Figure 2.5 (E, F)​). Taken 
together, the results suggest that Gs activation is sufficient to promote AC9 
internalization, and further underscores the idea that GPCR and AC9 trafficking are 
regulated by separate mechanisms. 
 
AC9 trafficking requires Gs but not β-arrestin 
Since receptor-independent activation of Gs, by mutation or by cholera toxin, was 
sufficient to promote AC9 accumulation in endosomes, we next considered whether Gs 
activation is necessary to promote this regulated trafficking process. To test this we 
examined a previously described line of HEK293 cells lacking all Gs function due to 
CRISPR-mediated ablation of the Gs alpha subunit ​(Stallaert et al. 2017)​. In these 
Gs-knockout (GsKO) cells, Flag-β2AR and AC9-EGFP colocalized at the plasma 
membrane in the absence of isoproterenol. While treatment with isoproterenol 
dramatically increased the number of internal punctae that were positive for Flag-β2AR, 
this was not the case for AC9-EGFP in these GsKO cells (​Figure 2.6 (A, C, D, I)​). This 
isoproterenol-induced AC9-EGFP trafficking defect could be rescued by expression of 
recombinant wild-type HA-Gs (​Figure 2.6 (B, C,​ ​D, J)​).  Together with the results 
presented above, these data indicate that activation of Gs is both necessary and 
sufficient to drive AC9 internalization but is not needed for β2AR trafficking. 
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Arrestins are known to be endocytic adaptor proteins essential for regulated 
internalization of the β2AR ​(Goodman et al. 1996)​. We next asked whether arrestins 
also regulate AC9 trafficking.  To test this we used a previously described line of 
HEK293 cells lacking both beta-arrestin isoforms (arrestins 2 and 3, or beta-arrestin-1 
and beta-arrestin-2)​(O’Hayre et al. 2017)​. In these arrestin 2/3 double-knockout cells 
(Arr DKO), HA-β2AR and AC9-EGFP localized to the plasma membrane in the absence 
of isoproterenol, as in wild type cells.  However, after application of isoproterenol, 
HA-β2AR remained restricted to the plasma membrane while AC9-EGFP still robustly 
localized to internal punctae (​Figure 2.6 (E, G, H, K)​). Addback of Arrestin 3 
(beta-arrestin-2) rescued this isoproterenol-induced internalization of HA-β2AR and 
AC9-EGFP still internalized (​Figure 2.6 (E, G, H, L)​). These data indicate that 
beta-arrestin, while necessary for regulated internalization of β2AR, is not necessary to 
regulate trafficking of AC9. Accordingly, although β2AR and AC9 colocalize to the early 
endosome as a result of agonist stimulation, the mechanistic basis for their regulated 
trafficking differs fundamentally. 
 
AC9 is sufficient to promote a β2AR-mediated signaling cascade from endosomes 
Both AC1 and AC9 are well known physiological effectors of beta-adrenergic signaling 
(Small et al. 2003; Tantisira 2005; Sadana, Rachna, and Dessauer 2009)​ and both are 
endogenously expressed in HEK293 cells, but neither AC1 nor AC9 is the dominant 
source of cAMP in these cells . Nevertheless, cAMP accumulation analysis after siRNA 
knockdown (​Figure 2.7 (C)​) indicated that both AC1 and AC9 make a statistically 
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significant contribution (​Figure 2.7 (D)​) to the overall cAMP response elicited by 
isoproterenol. Consistent with previous reports ​(Baldwin et al. 2019)​, AC9 knockdown 
did not have a detectable effect on the cellular response to forskolin whereas AC1 
knockdown produced a detectable reduction (​Figure 2.7 (D)​). Considering the 
differences in AC9 relative to AC1 trafficking, we asked if these isoforms are 
differentially activated depending on the location of receptor activation. 
 
We used a pharmacological approach to differentiate between receptor activation in 
endosomes and the plasma membrane. CGP12177 (CGP) is a high affinity β2AR 
antagonist that is well known to be membrane-impermeant ​(Staehelin et al. 1983)​ and 
thus selectively accesses receptors at the plasma membrane but not at the endosome. 
Alprenolol is a similarly high affinity antagonist that is relatively membrane-permeant, 
and thus can access receptors at both locations. Isoproterenol has previously been 
shown to promote β2AR activation in endosomes as well as the plasma membrane as 
detected using Nb80-EGFP, a conformational biosensor of β2AR activation ​(Irannejad 
et al. 2013)​. Verifying this, exposure of cells to isoproterenol (100 nM) for 30 minutes 
produced a clear Nb80-EGFP recruitment to β2AR-containing endosomes (​Figure 2.7 
(A)​). Subsequent addition of an excess concentration of alprenolol (10 µM) rapidly 
reversed Nb80-EGFP recruitment to endosomes, while β2AR was still detected in these 
membrane compartments. (​Figure 2.7 (A)​). In contrast, an excess concentration of 
CGP (10 µM) did not detectably reverse recruitment of Nb80-EGFP to β2AR-containing 
endosomes induced by the 30 minute pretreatment with isoproterenol (100 nM) (​Figure 
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2.7 (B)​). These results indicate that sequential treatment with isoproterenol and then 
CGP can selectively activate β2ARs at the endosome.  
 
The cellular cAMP response was measured in HEK293 cells that had been pretreated 
with isoproterenol and then exposed to either alprenolol or CGP. While both antagonists 
reduced the overall cAMP response, the inhibitory effect of alprenolol was significantly 
larger than that of CGP (​Figure 2.7 (G​, ​I)​). However, in cells depleted of AC9, this 
‘signal gap’ between the effects of alprenolol and CGP was eliminated (​Figure 2.7 (H, 
I)​). The statistically significant difference between the effects of CGP and alprenolol in 
control HEK293 cells suggests that there is a cAMP response originating from an 
internal pool of receptors. Further, since AC9 knockdown eliminates this difference 
(​Figure 2.7(C)​), we conclude that AC9 is a significant contributor to this 
internally-generated response. Consistent with the trafficking data, knockdown of AC1 in 
these cells had no significant effect on the signal gap between alprenolol and CGP 
(​Figure 2.7 (E, F, J)​).  
 
To further validate these findings, we over-expressed Flag-AC9 or Flag-AC1 in 
previously described AC3/6 double knockout (AC3/6 DKO) HEK293 cells 
(Soto-Velasquez et al. 2018)​. Because AC3 and AC6 generate the majority of cAMP in 
HEK293 cells, these cells provide a lower background on which to assess expressed 
isoforms. Overexpression of Flag-AC9 in AC3/6 DKO cells significantly increased the 
isoproterenol-induced cAMP response, consistent with previously reported results 
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(Soto-Velasquez et al. 2018)​.  A portion of this increase was not inhibited by CGP, 
whereas the entire increase in cellular cAMP elevation due to AC9 expression was 
eliminated by alprenolol (​Figure 2.7 (Q)​). Overexpression of Flag-AC1 in AC3/6 DKO 
cells also increased the isoproterenol-induced cAMP response as expected, but this 
increase was eliminated in the presence of either CGP or alprenolol (​Figure 2.7 (R)​). 
These data suggest that AC1 activity is restricted to the plasma membrane while AC9 is 
a significant contributor to β2AR-mediated signaling from the endosome. 
 
To determine whether the internally-generated cAMP response is endocytosis 
dependent, we examined the effect of DYNGO-4a, a chemical inhibitor of dynamin 
known to block endocytosis of β2AR ​(Irannejad et al. 2013)​. DYNGO-4a had little effect 
on the cellular cAMP response to sequential treatment with isoproterenol and then 
alprenolol, and this was the case both in control and AC9 siRNA knockdown conditions 
(​Figure 2.7 (K, L)​). In contrast, in cells subjected to sequential treatment with 
isoproterenol and then CGP, DYNGO-4a further enhanced the inhibitory effect of CGP 
on the cellular cAMP response. This was the case only in control conditions and the 
additive effect was lost after AC9 knockdown (​Figure 2.7 (M, N)​).  
 
This difference in sensitivity to endocytic blockade was additionally verified in cells 
overexpressing AC9 on the AC3/6 KO background. AC9 overexpression increased the 
overall isoproterenol-induced cAMP response, and it increased the CGP-resistant 
component without producing a detectable alp-resistant component. In the presence of 
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endocytic blockade by DYNGO-4a, the CGP-resistant component of the response was 
lost whereas inhibition by alprenolol was unchanged (​Figure 2.7 (S)​). In contrast, while 
AC1 overexpression also increased the isoproterenol-induced cAMP response in AC3/6 
DKO cells, there was no detectable CGP-resistant component added or additional effect 
of DYNGO-4a (​Figure 2.7 (T)​). These data provide functional evidence indicating that 
AC9 is a major contributor to the CGP-insensitive fraction of the β2AR-mediated cAMP 
response. Furthermore, this response is endocytosis-dependent, suggesting that the 
CGP-insensitive response represents an endosome-initiated signal cascade. AC1, while 
it contributes a similar (or larger) amount to the overall cellular cAMP response, does 
not contribute detectably to the endosome-initiated component.  
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2. 4 Discussion 
Membrane trafficking is a dynamically regulated system that is critical for homeostatic 
integrity of the cell. Endocytosis of signaling receptors has historically been viewed only 
as a mechanism to confer long-term homeostasis of signaling from the plasma 
membrane. This has been extensively described for the β2AR, with endocytosis 
controlling the surface availability of functional receptors and initiating receptor 
downregulation. According to this view, effectors function only at the plasma membrane 
and communicate to downstream targets solely by diffusion of second messengers. 
There is now compelling evidence that the endocytic network can function as a site of 
receptor-mediated signaling, and various GPCRs, including the β2AR, have been 
shown to activate Gs in endosomes ​(Irannejad et al. 2015; Vilardaga, Jean-Alphonse, 
and Gardella 2014; Lohse and Calebiro 2013)​. This raises the question of whether the 
endocytic network can differentially regulate G protein-linked effectors, enabling the 
spatial coordination of a signaling cascade with its downstream targets in the cell. We 
addressed this question by focusing on adenylyl cyclases as critical Gs-linked effectors, 
and demonstrate here the dynamic and regulated trafficking of AC9. AC9 is already 
known to be physiologically and clinically relevant to β2AR signaling ​(Sunahara 1996; 
Small et al. 2003; Tantisira 2005)​, and we show that AC9 is necessary and sufficient to 
promote the endosome-derived cAMP response in HEK293 cells.  
 
Our results indicate that AC1 trafficking is not regulated in the same way as AC9, 
establishing that AC trafficking is isoform-selective. However, we do not presently know 
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if AC9 accumulation in endosomes is unique to this isoform or more widespread. We 
anticipate the latter because a distantly related AC isoform has been localized to 
endosomes in ​D. discoideum ​(Kriebel et al. 2008)​, although whether or not these 
endosomes also contain the GPCR and cognate G protein has not been established. 
There is evidence that both AC2 and AC3 contribute functionally to the cAMP response 
elicited by GPCRs after endocytosis ​(Kriebel et al. 2008; Jean-Alphonse et al. 2017)​, 
but whether or not either isoform directly localizes to endosomes is presently unknown. 
Further, we note that soluble AC (sAC) also contributes to the endocytosis-dependent 
cAMP response ​(Inda et al. 2016)​. In this case the effect is almost certainly indirect 
because sAC is not known to be activated by Gs.  To our knowledge, the present 
results provide the first direct demonstration of dynamic trafficking of an adenylyl 
cyclase to endosomes that also contain an upstream activating GPCR and cognate G 
protein transductor, but whether this behavior is unique remains to be determined. 
 
One possible mechanism for adenylyl cyclase trafficking is that the receptor, G protein, 
and cyclase form both a signaling, and a trafficking unit. In this model, adenylyl cyclase 
internalization would be a direct physical consequence of arrestin-dependent 
recruitment of the receptor to clathrin coated pits. However, we demonstrate here that 
AC9 trafficking does not require beta-arrestins. Instead, we show that AC9 trafficking 
requires Gs and, further, that receptor independent activation of Gs is sufficient to 
induce AC9 internalization. We verify that the β2AR exhibits the opposite phenotype in 
that its trafficking requires beta-arrestin but not Gs. This indicates that the delivery of 
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AC9 and β2AR to endosomes, while both initiated by receptor activation, are regulated 
by distinct mechanisms. Future studies into the pathway of AC9 membrane trafficking 
and its coordination with, or divergence from, an activating receptor are required. 
 
The endosome is increasingly recognized as a relevant site for GPCR signaling.  This 
was initially thought to be restricted to G protein-independent signaling, particularly 
arrestin-mediated pathways ​(Shukla, Xiao, and Lefkowitz 2011)​, but endosomes are 
now understood to be sites of GPCR-mediated activation of heterotrimeric G proteins 
(Vilardaga et al. 2012; Thomsen et al. 2016)​. We identify a relevant adenylyl cyclase at 
endosomes and demonstrate that Gs can regulate both effector location in the cell and 
enzymatic activity. Spatiotemporal control of effector location by receptor activation has 
significant implications for therapeutic drug design. Given clear evidence that cAMP 
location in the cell is important for determination of downstream signaling consequences 
(Zaccolo and Pozzan 2002)​, it may be possible to achieve enhanced selectivity in drug 
action based on the subcellular location of second messenger production.  
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2.6 Materials & Methods 
Cell culture, expression constructs, and transfections    
HEK 293 cells (ATCC) were cultured in complete growth Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco) and supplemented with 10% fetal bovine serum (UCSF Cell 
Culture Facility). We note that AC9 most consistently internalized in cells that were not 
removed from the incubator for longer than 3 min during plating or transfection. 
HA-β2AR​(Tang et al. 1999; von Zastrow and Kobilka 1992)​, HA-V2R ​(Rochdi et al. 
2010)​, HA-MOR ​(Whistler and von Zastrow 1998)​, HA-V2R-T ​(Rochdi et al. 2010; 
Charest and Bouvier 2003)​, all described previously, were sub-cloned from Flag-tagged 
constructs. Nb80-EGFP was previously described ​(Irannejad et al. 2013)​. 
HA-G(alpha)s, G(beta-1), G(gamma-2) were gifts from Philip Wedegaertner. 
HA-G(alpha)s-Q227L, a previously described point mutant of Gs that is constitutively 
active ​(Masters et al. 1989)​, was made from the original construct using the 
QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) with the forward 
primer  5’-CGATGTGGGCGGCCTGCGCGATGAACGCCGC-3’. Flag-AC1, Flag-AC9 
from the Dessauer Lab, were originally described by ​(Premont et al. 1996; Krupinski et 
al. 1989; Hacker et al. 1998; Paterson et al. 2000)​. Flag-AC9-D442A (Catalytic inactive 
mutant) was also made from the original construct using QuikChange Kit with the 
forward primer 
5’-CCACTAGTCCAGTGTGGTGGAATTCGCCATGGACTACAAAGACGATGACGAC-3’. 
Transfections were carried out using Lipofectamine 2000 (Life Technologies) according 
to the manufacturer’s protocol. Cells were transfected 48 hours before experiments.  
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 siRNA knockdown of AC1 and AC9 expression in HEK293 cells was carried out using 
Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s protocol. 
Cells were transfected 72 hours before experiments. Knockdown of AC1 used the 
siRNA CCGGGCGGTTCAGACCTTCAA and AC9 knockdown used 
CTGGGCATGAGGAGGTTTAAA. 
 
Primary cultures of human airway smooth muscle cells were established as described 
previously ​(Tsvetanova et al. 2016)​. Cells were passaged no more than 5 times using 
Trypsin-EDTA (Life Technologies) and maintained in 10% FBS in DMEM. 
 
Gs knockout ​(Stallaert et al. 2017)​ and beta-arrestin-1/2 double knockout ​(O’Hayre et al. 
2017)​ HEK293 cells were previously described .  AC3 / AC6 double knockout HEK293 
cells were also described previously ​(Soto-Velasquez et al. 2018)​ and were provided as 
a generous gift by Drs. Monica Soto-Valasquez and Val Watts (Purdue University). 
Cells were passaged using PBS-EDTA and maintained in 10% FBS in DMEM. 
 
Cholera Toxin (Sigma) was administered to cells for 16 hours overnight treatment at 10 
ng/ml concentration in 10% FBS in DMEM.  
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Antibodies 
Antibodies used were rabbit anti-Flag (Sigma), mouse anti-Flag M1 (Sigma), mouse 
anti-Flag M2 (Sigma), mouse anti-HA 16B12 (Biolegend), rat anti-HA (Roche), goat 
anti-AC9 (Santa Cruz Biotech), mouse anti-Golgin-97 (Thermo), rabbit anti-calnexin 
(Cell Signaling), mouse anti-Sodium/Potassium ATPase (Fisher). 
 
Fixed cell confocal imaging 
Cells were transfected with the indicated construct(s) and then plated on glass 
coverslips coated with poly-L-lysine (​0.0001%, ​Sigma) 24 hours later. For antibody 
feeding assays, cells were: (1) placed on ice and rinsed with ice-cold 
phosphate-buffered saline (PBS), (2) labeled by the addition of antibodies diluted 
1:1000 in DMEM for 10 minutes, and (3) rinsed with room temperature PBS and allowed 
to traffic for 30 minutes by the addition of 37​°​C​ ​fresh media (DMEM + 10% fetal bovine 
serum) with or without a saturating concentration of β2AR agonist (10 ​μ​M isoproterenol, 
Sigma), V2R agonist (10 µM arginine-vasopressin, Sigma), MOR agonist (10 µM 
DAMGO, Sigma), or forskolin (10 µM, Sigma). For all assays, cells were rinsed with cold 
PBS and fixed by incubation in 3.7% formaldehyde (Fisher Scientific) diluted in modified 
BRB80 buffer (80mM PIPES, 1mM MgCl​2​, 1mM CaCl​2​, pH 6.8) for 20 minutes at room 
temperature. Cells were then blocked in 2% Bovine Serum Albumin (Sigma) in PBS with 
permeabilization by 0.2% triton X-100 (Sigma). Primary antibody labeling was 
performed by the addition of antibodies diluted 1:1000 in blocking/ permeabilization 
buffer for one hour at room temperature. Secondary labeling was performed by addition 
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of the following antibodies diluted at 1:500 in blocking/ permeabilization buffer for 20 
minutes at room temperature: Alexa Fluor 555 or 488 donkey anti-mouse (Invitrogen), 
Alexa Fluor 555 or 488 donkey anti-rabbit (Invitrogen), Alexa Fluor 488 or 555 goat 
anti-rat (Invitrogen), or Alexa Fluor 488 donkey anti-sheep (Life Technologies). 
Specimens were mounted using ProLong Gold antifade reagent (Life Technologies). 
 
Fixed cells were imaged by spinning disc confocal microscope (Nikon TE-2000 with 
Yokogawa confocal scanner unit CSU22) using a 100X NA 1.45 objective.​ A 488 nm 
argon laser and a 568 nm argon/krypton laser (Melles Griot) were used as light 
sources. 
 
Microscope image acquisition and image analysis 
Spinning disc images were collected using an electron multiplying CCD camera (Andor 
iXon 897) operated in the linear range controlled by Micro-Manager software 
(https://www.micro-manager.org). Images were processed at full bit depth for all 
analysis and rendered for display by converting to RGB format using ImageJ software 
(http://imagej.nih.gov/ij) and linear look up table. The number of endosomes was 
quantified by thresholding images and the ParticleTracker ImageJ plugin. 
 
Live-cell confocal imaging 
Live cell imaging was carried out using Yokagawa CSU22 spinning disk confocal 
microscope with a ×100, 1.4 numerical aperture, oil objective and a CO2 and 37 °C 
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temperature-controlled incubator. A 488 nm argon laser and a 568 nm argon/krypton 
laser (Melles Griot) were used as light sources for imaging EGFP and Flag signals, 
respectively. Cells expressing both Flag-tagged receptor and the indicated 
nanobody–EGFP were plated onto glass coverslips. Receptors were surface labelled by 
addition of M1 anti-Flag antibody (1:1000, Sigma) conjugated to Alexa 555 (A10470, 
Invitrogen) to the media for 30 min, as described previously. Indicated agonist 
(isoprenaline, Sigma) or antagonist (CGP-12177, Tocris) (alprenolol, Sigma) were 
added and cells were imaged every 3 s for 20 min in DMEM without phenol red 
supplemented with 30 mM HEPES, pH 7.4 (UCSF Cell Culture Facility). Time-lapse 
images were acquired with a Cascade II EM charge-coupled-device (CCD) camera 
(Photometrics) driven by Micro-Manager 1.4 ​(​http://w​ww.micro-manager.org​)​. 
Endosome Pulldown 
Cells were transfected with the indicated construct(s) 48 hours before lysis and plated 
onto 60mm cell culture dishes 24 hours before lysis. Cells were allowed to traffic for 30 
minutes by the addition of 37​°​C​ ​fresh media (DMEM + 10% fetal bovine serum) with or 
without a saturating concentration of the indicated agonist. Cells were then placed on 
ice, washed with ice-cold PBS, and scraped into an isotonic homogenization buffer 
(10mM HEPES, 100mM KCl, 25mM sucrose, Complete protease inhibitor (Roche), pH 
7.2) and passaged 20 times through a 22 G BD PrecisionGlide Needle. Whole cell 
lysates were then spun down at 1000 G for 10 minutes at 4​°C and the pellets discarded. 
The supernatant was then bound to Early Endosome Antigen 1 mouse antibody (1:250, 
Fisher Scientific) and anti-mouse IgG magnetic microbeads (Miltenyi Biotech) overnight. 
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Endosomes were then bound to magnetic columns which were blocked with 3% BSA 
and washed with PBS. Endosomes were then eluted with 0.1% Triton-X and 
characterized by western blot.  
 
Surface Biotinylation 
Cells were transfected with the indicated construct(s) 48 hours before lysis and plated 
onto 60mm cell culture dishes coated with poly-L-lysine (0.0001%, Sigma) 24 hours 
before lysis. Cells were allowed to traffic for 30 minutes by the addition of 37​°​C​ ​fresh 
media (DMEM + 10% fetal bovine serum) with or without a saturating concentration of 
the indicated agonist. Cells were then placed on ice, washed with ice-cold PBS, and 
then surface labeled with EZ-link Sulfo-NHS-biotin (Pierce) for 30 min, rocking at 4​°C. 
Reaction was then quenched with tris buffered saline (TBS) twice for 10 min. ​Cells were 
then placed on ice, washed with ice-cold PBS, and scraped into an isotonic 
homogenization buffer (10mM HEPES, 100mM KCl, 25mM sucrose, Complete protease 
inhibitor (Roche), pH 7.2) and passaged 20 times through a 22 G BD PrecisionGlide 
Needle. Cell lysate was then bound to streptavidin agarose resin (Thermo) overnight. 
Resin was spun down and the supernatant discarded, resuspended and washed in 
ice-cold PBS, and characterized by western blot. 
 
Luminescence-based rapid cAMP assay 
HEK293 cells were transfected with a plasmid encoding a cyclic-permuted luciferase 
reporter construct, based on a mutated RIIβB cAMP-binding domain from PKA 
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(pGloSensor-20F, Promega), which produces rapid and reversible cAMP-dependent 
activation of luciferase activity in intact cells. Cells were plated in 24-well dishes 
containing approximately 200,000 cells per well in 500 μl DMEM without phenol red and 
no serum and equilibrated to 37 °C in a light-proof cabinet. An image of the plate was 
focused on a 512 × 512 pixel electron multiplying CCD sensor (Hamamatsu 
C9100-13), cells were equilibrated for 1 h in the presence of 250 μg ml​−1​ luciferin 
(Biogold), and sequential luminescence images were collected every 10 s to obtain 
basal luminescence values. The camera shutter was closed, the cabinet opened and 
the indicated concentration of isoprenaline was bath applied, with gentle manual rocking 
before replacing in the dark cabinet and resuming luminescence image acquisition. In 
endocytic manipulation experiments, cells were pre-incubated with 30 μM Dyngo-4a 
(abcam Biochemicals) for 15 min. Every 10 s, sequential images were acquired using 
Micro-Manager (​http://www.micro-manager.org​) and integrated luminescence intensity 
detected from each well was calculated after background subtraction and correction for 
vignetting using scripts written in MATLAB (MathWorks). In each multiwell plate, and for 
each experimental condition, a reference value of luminescence was measured in the 
presence of 5 μM forskolin, a manipulation that stimulates a moderate amount of 
receptor-independent activation of adenylyl cyclase. The average luminescence 
value—measured across duplicate wells—was normalized to the maximum 
luminescence value measured in the presence of 5 μM forskolin. 
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 Statistical Analysis 
Results are displayed as mean of results from each experiment or data set, as indicated 
in Figure legends. The statistical significance between conditions for experiments with 
two conditions was calculated using paired, two tailed t-tests. ​All statistical calculations 
were performed using Excel (Microsoft Office) or Prism (GraphPad). The threshold for 
significance was p<0.05 and the coding for significance is reported as follows: (n.s.) 
p>0.05, (*) p≤0.05, (**) p≤0.01. 
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2.8 Figures 
 
 
Figure 2.1: β2AR activation causes redistribution of AC9 but not AC1. 
(A)​  Representative confocal imaging of HEK293 cells coexpressing HA-β2AR and 
Flag-AC1 after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 
µm. ​(B)​ Representative confocal images of HEK293 cells coexpressing HA-β2AR and 
Flag-AC9 after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 
µm. ​(C)​ Quantification of internal puncta that are β2AR or AC1/9 positive, taken from 
wide field images (see: Figure 2.1M, 2.1N) [mean±SEM; n=3 experiments, 10 visual 
fields and 200+ cells per condition]. ** P < 0.01 by two-tailed t-test. ​(D)​ Quantification of 
cells with >10 internal puncta that are β2AR or AC1/9 positive, taken from wide field 
74 
images (see: Figure 2.1M, 2.1N) [mean±SEM; n=3 experiments, 10 visual fields and 
200+ cells per condition]. ** P < 0.01 by two-tailed t-test. ​(E-F)​ Representative confocal 
imaging of HEK293 cells expressing Flag-AC1 ​(E)​ or Flag-AC9 ​(F) ​after treatment with 
10 µM isoproterenol or control for 30 min. Scale Bar is 8 µM. ​(G-H)​ Representative 
confocal imaging of HEK293 cells expressing Flag-AC1 ​(G) ​or Flag-AC9 ​(H)​. Cells were 
stimulated with 100 nM isoproterenol for 30 min with or without 15 min of pretreatment 
with 10 µM alprenolol. ​(I)​ Representative confocal images of primary culture human 
airway smooth muscle cells immunostained for endogenous AC9 after treatment with 10 
µM isoproterenol or control for 30 min. Scale Bar is 16 µm. ​(J)​ Quantification of the 
number of endosomes in cells from ​(Figure 2.1 E-H)​ [mean±SEM; n=3 experiments, 25 
cells per condition].  
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Figure 2.1: β2AR activation causes redistribution of AC9 but not AC1. 
(K) ​Quantification of the in vitro cAMP response by pcDNA3 control, untagged AC9, and 
Flag-tagged AC9 to 300 nM Gs (alpha subunit). ​(L) ​Quantification of the cAMP 
response to 10µM isoproterenol in control HEK293 cells and cells overexpressing 
Flag-AC1, Flag-AC9, or Flag-AC9-D442A. [mean±SEM; n=3 experiments] ​(M) ​Wide 
field images of HEK293 cells coexpressing HA-β2AR and Flag-AC9, after treatment with 
10 µm isoproterenol or control for 30 min. Scale bar is 16 µm. ​(N) ​Wide field images of 
HEK293 cells coexpressing HA-β2AR and Flag-AC1, after treatment with 10 µm 
isoproterenol or control for 30 min. Scale bar is 16 µm. 
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Figure 2.2: Surface AC9 is internalized to early endosomes upon adrenergic 
stimulation. (A-B)​ Representative confocal images of HEK293 cells expressing 
Flag-AC1 ​(A)​ or Flag-AC9 ​(B)​ after treatment with 10 µM isoproterenol or control for 30 
min and stained for endogenous EEA1. Scale bar is 8 µm. ​(C) ​Representative western 
blot of a fraction isolated using antibodies to EEA1. Lanes 1-2 correspond to control 
HEK293 cells, lanes 3-4 to cells coexpressing Flag-AC9 and HA-β2AR, and lanes 5-6 to 
cells coexpressing Flag-AC1 and HA-β2AR. ​(D)​ Quantification of recovery of HA-β2AR, 
Flag-AC9 and Flag-AC1 in the endosome fraction relative to cell lysate. [mean±SEM; 
n=7 experiments]. ** P < 0.01 by two-tailed t-test. ​(E)​ Representative western blot of the 
surface exposed fraction isolated by surface labeling with Sulfo-NHS-biotin and purified 
with streptavidin. Lanes 1-2 correspond to cells coexpressing Flag-AC9 and HA-β2AR, 
and lanes 3-4 to cells coexpressing Flag-AC1 and HA-β2AR. ​(F)​ Quantification of 
recovery of HA-β2AR, Flag-AC9 and Flag-AC1 in the surface biotinylated fraction 
relative to total cell lysate. [mean±SEM; n=7 experiments]. ** P < 0.01 by two-tailed 
t-test.​ (G) ​Full western blot of the endosome fraction vs total cell lysate, probed for 
cellular markers Giantin (Golgi), Na/K pump (plasma membrane), calnexin 
(endoplasmic reticulum). Quantification of 3 such experiments.
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Figure 2.3: V2R, but not MOR, can cause AC9 to localize to early endosomes. 
(A-C) ​Representative confocal imaging of HEK293 cells coexpressing Flag-AC9 and 
HA-V2R ​(A)​, HA-MOR ​(B)​, or HA-V2R-trunc ​(C)​, after treatment with 10 µM agonist 
(AVP or DAMGO) or control for 30 min. Scale Bar is 8 µm. ​(D)​ Quantification of internal 
puncta that are V2R, MOR, V2R-T, or AC1/9 positive, taken from wide field images 
(see: Figure 3J, 3K, 3L) [mean±SEM; n=3 experiments, 10 visual fields and 200+ cells 
per condition]. ** P < 0.01 by two-tailed t-test. ​(E)​ Quantification of cells with >10 
internal puncta that are V2R, MOR, V2R-T or AC1/9 positive, taken from wide field 
images (see: Figure 3J, 3K, 3L) [mean±SEM; n=3 experiments, 10 visual fields and 
200+ cells per condition]. ** P < 0.01 by two-tailed t-test. ​(F) ​Representative confocal 
imaging of HEK293 cells expressing Flag-AC9, after treatment with 10 µM AVP or 
control for 30 min. Scale Bar is 8 µm.  
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Figure 2.3: V2R, but not MOR, can cause AC9 to localize to early endosomes.  
(G) ​Representative western blot of the surface biotinylated fraction from HEK293 cells 
expressing Flag-AC9 (lanes 1-2) or coexpressing HA-V2R and Flag-AC9 (lanes 3-4) 
[mean±SEM; n=3 experiments]. ​(H) ​Representative western blot of the surface 
biotinylated fraction from HEK293 cells coexpressing HA-V2R and Flag-AC9 (lanes 
1-2), HA-V2R-T and Flag-AC9 (lanes 3-4), or HA-MOR and Flag-AC9 (lanes 5-6). ​(I) 
Recovery of tagged protein in the surface biotinylated fraction relative to the total cell 
lysate as seen in ​(H)​ [mean±SEM; n=7 experiments]. ** P < 0.01 by two-tailed t-test. ​(J) 
Wide field images of HEK293 cells coexpressing HA-V2R and Flag-AC9, after treatment 
with 10 µm arginine vasopressin (AVP) or control for 30 min. Scale bar is 16 µm. ​(K) 
Wide field images of HEK293 cells coexpressing HA-MOR and Flag-AC9, after 
treatment with 10 µm ​[D-Ala​2​, N-MePhe​4​, Gly-ol]-enkephalin (DAMGO) ​or control for 30 
min. Scale bar is 16 µm. ​(L) ​Wide field images of HEK293 cells coexpressing 
HA-V2R-trunc and Flag-AC9, after treatment with 10 µm arginine vasopressin (AVP) or 
control for 30 min. Scale bar is 16 µm. 
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Figure 2.4: Forskolin-promoted cAMP accumulation is insufficient to drive AC9 
internalization. (A) ​Representative confocal imaging of HEK293 cells coexpressing 
HA-β2AR and Flag-AC9 were treated with 10 µM FSK or control for 30 min. Scale Bar is 
8 µm. ​(B) ​Representative confocal imaging of HEK293 cells coexpressing HA-β2AR 
and Flag-AC1 were treated with 10 µM FSK or control for 30 min. Scale Bar is 8 µm. ​(C) 
Quantification of internal puncta that are β2AR or AC1/9 positive, taken from wide field 
images (see: Figure 4I, 4J) [mean±SEM; n=3 experiments, 10 visual fields and 200+ 
cells per condition]. ** P < 0.01 by two-tailed t-test. ​(D)​ Quantification of cells with >10 
internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see: 
Figure 4I, 4J) [mean±SEM; n=3 experiments, 10 visual fields and 200+ cells per 
condition]. ** P < 0.01 by two-tailed t-test.​ (E)​ Representative western blot of the surface 
biotinylated fraction of cells from ​(A,C)​. ​(F) ​Quantification of the percent loss from the 
surface biotinylated fraction relative to the total cell lysate as seen in ​(E)​ [mean±SEM; 
n=5 experiments].  
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Figure 2.4: Forskolin-promoted cAMP accumulation is insufficient to drive AC9 
internalization. (G)​ Representative confocal imaging of HEK293 cells coexpressing 
HA-β2AR and the catalytic inactive mutant Flag-AC9-D442A were treated with 10 µM 
isoproterenol or control for 30 min. Scale Bar is 8 µm. ​(H) ​Representative confocal 
imaging of HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated with 10 
µM FSK and 10 µM IBMX or control for 30 min. Scale Bar is 8 µm. ​(I) ​Representative 
wide-field imaging of HEK293 cells coexpressing HA-β2AR and  Flag-AC9 which were 
treated with 10 µM FSK or control for 30 min. ​(J) ​Representative wide-field imaging of 
HEK293 cells coexpressing HA-β2AR and  Flag-AC1 which were treated with 10 µM 
FSK or control for 30 min. 
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Figure 2.5: Gs activation is sufficient for AC9 to localize to early endosomes. 
(A)​ Representative confocal imaging of HEK293 cells cells coexpressing Flag-AC9, 
G​s​β, G​s​ˠ and either HA-G​s​⍺ (HA-Gs) or HA-G​s​⍺-CA (HA-GsCA). ​(B)​ Representative 
confocal imaging of HEK293 cells coexpressing Flag-AC1, G​s​β, G​s​ˠ and either HA-G​s​⍺ 
(HA-Gs) or HA-G​s​⍺-CA (HA-GsCA). ​(C)​ Quantification of internal puncta that are Gs or 
AC1/9 positive, taken from wide field images (see: Figure 5K, 5L) [mean±SEM; n=3 
experiments, 10 visual fields and 200+ cells per condition]. ** P < 0.01 by two-tailed 
t-test. ​(D)​ Quantification of cells with >10 internal puncta that are Gs or AC1/9 positive, 
taken from wide field images (see: Figure 5K, 5L) [mean±SEM; n=3 experiments, 10 
visual fields and 200+ cells per condition]. ** P < 0.01 by two-tailed t-test.  
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Figure 2.5: Gs activation is sufficient for AC9 to localize to early endosomes.  
(E)​ Representative western blot of an EEA1+ fraction from HEK293 cells coexpressing 
Flag-AC9 and HA-Gs (lanes 1 and 3) or Flag-AC9 and HA-GsCA (lanes 2 and 4) and 
after treatment with 10 µM isoproterenol (lanes 1-2) or control (lanes 3-4) for 30 min. ​(F) 
Quantification of the fraction of Flag-AC9 and HA-Gs/HA-GsCA recovered in the EEA1+ 
fraction ​(E)​ relative to total cell lysate. [mean±SEM; n=3 experiments] * P < 0.05 ** P < 
0.01 by two-tailed t-test. ​(G) ​Representative western blot of an EEA1 positive endosome 
fraction from HEK293 cells coexpressing Flag-AC9, G​s​β, G​s​ˠ and HA-Gs (lane 1) or 
HA-GsCA (lane 2). ​(H) ​Quantification of endosome enrichment of Flag-AC9 and HA-Gs 
or HA-GsCA as seen in ​(G)​ by normalizing to the EEA1 signal. [mean±SEM; n=5 
experiments] ** P < 0.01 by two-tailed t-test. ​(I) ​Representative western blot of an EEA1 
positive endosome fraction from HEK293 cells coexpressing Flag-AC1, G​s​β, G​s​ˠ and 
HA-Gs (lane 1) or HA-GsCA (lane 2). ​(J) ​Quantification of endosome enrichment of 
Flag-AC1 and HA-Gs or HA-GsCA as seen in ​(I)​ by normalizing to the EEA1 signal. 
[mean±SEM; n=5 experiments] ** P < 0.01 by two-tailed t-test.  
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Figure 2.5: Gs activation is sufficient for AC9 to localize to early endosomes.  
(K) ​Representative wide-field imaging of HEK293 cells coexpressing HA-Gs (wild type) 
or HA-Gs-Q227L and Flag-AC9. ​(L) ​Representative wide-field imaging of HEK293 cells 
coexpressing HA-Gs (wild type) or HA-Gs-Q227L and Flag-AC1. ​(M) ​Representative 
confocal imaging of HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated 
with 100 nM cholera toxin overnight. Scale Bar is 8 µm. ​(N)​ Representative confocal 
imaging of HEK293 cells coexpressing HA-β2AR and Flag-AC1 were treated with 100 
nM cholera toxin overnight. 
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Figure 2.6: Gs activation is necessary for arrestin-independent endocytosis of 
AC9 
(A-B) ​Representative confocal imaging of Gs knockout (GsKO) HEK293 cells 
coexpressing Flag-β2AR, AC9-EGFP, and either pcDNA3 ​(A) ​or wild-type HA-Gs 
rescue ​(B)​. ​(C)​ Quantification of internal puncta that are β2AR or AC9 positive, taken 
from wide field images (see: Figure 6I, 6J) [mean±SEM; n=3 experiments, 10 visual 
fields and 200+ cells per condition]. ** P < 0.01 by two-tailed t-test. ​(D)​ Quantification of 
cells with >10 internal puncta that are β2AR or AC9 positive, taken from wide field 
images (see: Figure 6I, 6J) [mean±SEM; n=3 experiments, 10 visual fields and 200+ 
cells per condition]. ** P < 0.01 by two-tailed t-test.  
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Figure 2.6: Gs activation is necessary for arrestin-independent endocytosis of 
AC9 (E-F) ​Representative confocal imaging of Arrestin2/3 double knockout (Arr dKO) 
cells coexpressing Flag-β2AR, AC9-EGFP, and either pcDNA3 ​(D)​ or HA-Arrestin 3 
rescue ​(F)​. ​(G)​ Quantification of internal puncta that are β2AR or AC9 positive, taken 
from wide field images (see: Figure 6K, 6L) [mean±SEM; n=3 experiments, 10 visual 
fields and 200+ cells per condition]. ** P < 0.01 by two-tailed t-test. ​(H)​ Quantification of 
cells with >10 internal puncta that are Gs or AC1/9 positive, taken from wide field 
images (see: Figure 6K, 6L) [mean±SEM; n=3 experiments, 10 visual fields and 200+ 
cells per condition]. ** P < 0.01 by two-tailed t-test. 
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Figure 2.6: Gs activation is necessary for arrestin-independent endocytosis of 
AC9 (I) ​Representative wide-field imaging of Gs-knockout HEK293 cells coexpressing 
HA-β2AR and Flag-AC9 were treated with 10 µM isoproterenol for 30 min. Scale Bar is 
8 µm. ​(J)​ Representative wide-field imaging of Gs-knockout HEK293 cells coexpressing 
Gs (wild type) HA-β2AR and Flag-AC9 were treated with 10 µM isoproterenol for 30 
min. Scale Bar is 8 µm. ​(K) ​Representative wide-field imaging of Arrestin 2/3 double 
knockout HEK293 cells coexpressing HA-β2AR and Flag-AC9 were treated with 10 µM 
isoproterenol for 30 min. Scale Bar is 8 µm. ​(L)​ Representative wide-field imaging of 
Arrestin 2/3 double knockout HEK293 cells coexpressing Arrestin 2, HA-β2AR and 
Flag-AC9 were treated with 10 µM isoproterenol for 30 min.  
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Figure 2.7: AC9 is a significant contributor to the β2AR-mediated cAMP response 
from endosomes. (A)​ Recruitment of conformational biosensors to β2AR-containing 
endosomes is reversed by application of the membrane permeable antagonist 
alprenolol for 20 min. Scale Bar is 8 µm.​ (B) ​Recruitment of conformational biosensors 
to β2AR-containing endosomes is unaffected by application of the membrane 
impermeable antagonist CGP12177 for 20 min. Scale Bar is 8 µm.  
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Figure 2.7: AC9 is a significant contributor to the β2AR-mediated cAMP response 
from endosomes. (C)​ Percent knockdown of AC9 and AC1 in HEK293 cells as 
determined by qPCR. [mean±SEM; n=3 experiments]. ​(D) ​Effect of siRNA knockdown of 
AC9 and AC1 expression in HEK293 cells on the cAMP response to 10 µM FSK and 10 
µM isoproterenol stimulation [mean±SEM; n=4 experiments] * P < 0.05 by two-tailed 
t-test. ​(E) ​Representative normalized β2AR-mediated cAMP response in control 
HEK293 cells pretreated with 100nM isoproterenol and exposed to supersaturating 
antagonist conditions (10µM CGP12177, 10µM alprenolol). ​(F) ​Representative 
normalized β2AR-mediated cAMP response in AC1 knockdown HEK293 cells 
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pretreated with 100nM isoproterenol and exposed to supersaturating antagonist 
conditions (10µM CGP12177, 10µM alprenolol).  ​(G) ​Representative normalized 
β2AR-mediated cAMP response in control HEK293 cells pretreated with 100nM 
isoproterenol and exposed to supersaturating antagonist conditions (10µM CGP12177, 
10µM alprenolol). ​(H) ​Representative normalized β2AR-mediated cAMP response in 
AC9 knockdown HEK293 cells pretreated with 100nM isoproterenol and exposed to 
supersaturating antagonist conditions (10µM CGP12177, 10µM alprenolol). ​(I) 
Quantification of the maximum cAMP response in control and in AC9 siRNA knockdown 
HEK293 cells pretreated with 100nM isoproterenol and exposed to supersaturating 
conditions of membrane permeable antagonist (10µM alprenolol) or membrane 
impermeable antagonist (10µM CGP12177). [mean±SEM; n=4 experiments] ​(J) 
Quantification of the maximum cAMP response in control in AC1 siRNA knockdown 
HEK293 cells pretreated with 100nM isoproterenol and exposed to supersaturating 
conditions of membrane permeable antagonist (10µM alprenolol) or membrane 
impermeable antagonist (10µM CGP12177). [mean±SEM; n=4 experiments].  
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Figure 2.7: AC9 is a significant contributor to the β2AR-mediated cAMP response 
from endosomes. (K) ​Representative cAMP response to pretreatment with DYNGO-4a 
and 100nM isoproterenol, and exposure to 10 µM alprenolol in AC9 knockdown or 
control HEK293 cells. ​(L)​ Quantification of the maximum cAMP response as seen in ​(A) 
[mean±SEM; n=3 experiments].​ (M) ​Representative cAMP response to pretreatment 
with DYNGO-4a and 100nM isoproterenol, and exposure to 10 µM CGP12177 in AC9 
knockdown or control HEK293 cells. ​(N)​ Quantification of the maximum cAMP response 
as seen in ​(C) ​[mean±SEM; n=3 experiments]. ​(O) ​Representative cAMP response to 
stimulation with 10 µM FSK and 10 µM IBMX or control under conditions of siRNA 
knockdown of AC9 expression or control (ASD). ​(P)​ Quantification of the maximum 
cAMP response as seen in ​(E) ​[mean±SEM; n=3 experiments].  
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Figure 2.7: AC9 is a significant contributor to the β2AR-mediated cAMP response 
from endosomes. (Q)​ Quantification of the maximum cAMP response in AC3/6KO 
HEK293 cells overexpressing control or AC9. Cells were pretreated with 100nM 
isoproterenol and exposed to supersaturating conditions of membrane permeable 
antagonist (10µM alprenolol) or membrane impermeable antagonist (10µM CGP12177). 
[mean±SEM; n=4 experiments]. ​(R)​ Quantification of the maximum cAMP response in 
AC3/6KO HEK293 cells overexpressing control or AC1. Cells were pretreated with 
100nM isoproterenol and exposed to supersaturating conditions of membrane 
permeable antagonist (10µM alprenolol) or membrane impermeable antagonist (10µM 
CGP12177). [mean±SEM; n=4 experiments]. ​(S) ​Quantification of the maximum cAMP 
response in AC3/6KO HEK293 cells overexpressing AC9. Cells were pretreated with 
DYNGO-4a and then 100nM isoproterenol, and supersaturating antagonist conditions 
(10µM CGP12177, 10µM alprenolol). ​(T) ​Quantification of the maximum cAMP 
response in AC3/6KO HEK293 cells overexpressing AC1. Cells were pretreated with 
DYNGO-4a and then 100nM isoproterenol, and supersaturating antagonist conditions 
(10µM CGP12177, 10µM alprenolol).  
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Chapter 3:  
An acute CO2 gradient is sufficient to inhibit 
isoproterenol-induced AC9 internalization in HEK293 
cells 
André M. Lazar conceived the project and performed all of the experiments and data 
analysis. Mark von Zastrow performed experiments. André M. Lazar and Mark von 
Zastrow wrote the manuscript. 
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3.1 Abstract 
G Protein Coupled Receptors (GPCR) are the largest group of signal-transducing 
receptors in mammals and are involved in a vast array of cellular responses. The 
endocytic network has long been recognized to regulate GPCR signaling, either by 
arrest or by delivery of signaling cascades to effector locations in the cell. However, 
membrane trafficking of adenylyl cyclase isoforms and the regulatory mechanisms 
involved is still a nascent field. Here we described the first observation that an acute 
negative CO2 gradient can inhibit AC9 endocytosis. We further show that this inhibition 
only recovers after 5 days, indicating a change in genetic expression. This unexpected 
cellular response to removal from the incubator for 3 minutes may have great 
implications on GPCR signaling studies and cell culture techniques more generally. 
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3.2 Introduction 
This project has been unusual in many ways, and that is reflected in this chapter. No 
line of scientific investigation is ever truly finished, but in this case, this project is very 
much ongoing and there are several important questions still left. It would not be 
overstating it to say that this project has really only reached its starting point, which 
makes writing a thesis chapter about this topic so strange. However, no review of my 
work as a graduate student in the von Zastrow lab would be complete without a 
summary of the progress made here. This chapter is therefore written as more of a 
report of our progress rather than a conclusive document, and follows a fairly personal 
chronological account of experimentation.  
 
Early progress in the data presented in Chapter 2 was rapid. Once a basic protocol was 
established for plating, transfecting, fixing and staining HEK293 cells with AC9, we were 
able to test many conditions and greatly expand our knowledge on the subject. Within 
two years of the project starting, we had put together enough data to try submitting an 
early manuscript. This project was moving so quickly and positive results were so 
forthcoming that others in the lab, including classmate Grace Peng, were attempting to 
direct their efforts towards exploring the burgeoning field of adenylyl cyclase trafficking.  
 
By the time we had received reviewer comments from our initial manuscript submission, 
Grace had found that she had difficulty reproducing the basic experiment at the core of 
the paper. She was unable to consistently fix and stain Flag-AC9 in endosomes after 
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adrenergic stimulation, although she did consistently fix and stain HA-B2AR there under 
the same conditions. Grace and I began troubleshooting the protocol together for a few 
months with little insights or success, and she eventually moved to other projects. 
Having discontinued responding to reviewer comments at this point, I began to 
troubleshoot the protocol in earnest.  
 
It was difficult to move forward on troubleshooting the protocol by myself, because the 
AC9 trafficking continued to consistently present in my hands. While we understand 
now that timing during plating and transfection is important, in the moment (late 2016 
and early 2017) it seemed impossible that the same protocol, done side by side and 
with the same reagents, could produce different effects. Our inability to achieve 
consistent results in what was believed to be a well controlled experiment was 
extremely puzzling. Some in the lab cast a doubtful eye on the validity of my data, and 
the strain on my mental and physical health proved a significant roadblock.  
 
In early 2017 I began working more closely with Mark, who like Grace had difficulty 
showing consistent AC9 internalization. Important to note is that it was inconsistent, not 
nonexistent. Experiments had internal consistency in that if we observed AC9 
internalization or not, it was typically in all cells. We came to term this as ‘positive’ or 
‘negative’ results. The classification of an experiment being ‘positive’ or ‘negative’ began 
with Grace, but was fully explored when working with Mark. We rigorously tested every 
reagent and step of the protocol, reducing or eliminating variables along the way. It 
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ultimately took us two more years (summer 2019) to reach a point at which we had 
consistent results in both our hands and gotten a postdoc in the lab, Braden Lobingier, 
to recapitulate them independently.  
 
If the definition of insanity is repeating something and expecting a different result, the 
work that Mark and I did on this project may qualify. Seemingly identical experiments 
were performed over and over again with different results, and every time we thought 
we’d found a clue, success eluded us. We speculated jokingly about magic, or juju, or 
cooties, largely because Mark often produced positive results under my watchful eye, 
but negative ones when I wasn’t observing him. We now know this was because his 
timing was crisper under observation, not magic. This has been the most confusing 
experience in my, and many others, scientific career, but the implications of our findings 
on GPCR signaling and cell culture techniques may be quite large. Our discovery of a 
sensitivity to acute exposure to a negative CO2 gradient is a novel phenomenon that 
will be a fascinating field to explore. 
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3.3 Results 
Initial protocol 
Day 0: Prepare slides: flame each slide and place in 12-well plate. Coat with 1:1000 
Poly-L Lysine (in water) solution for 15 min. Aspirate and dry for 15 min at least. Wash 
3X with water and dry 15 min at least. Plate HEK293 cells on slides at 40-50% 
confluence. 
Day 1: Transfect cells (per well): 
-300ng AC9 + 300ng B2AR + 100uL optimem 
-1uL lipofectamine 2000 + 100uL optimem 
Day 2: Exchange media 
Day 3: Fix and Stain. 
1. Surface label receptor with HA antibody for 10 minutes.  
2. Stimulate for 30 min with 10uM isoproterenol. 
3. Wash 1x cold PBS. 
4. Fix cells with 4% formaldehyde in modified BRB80 buffer (80mM PIPES, 
1mM MgCl​2​, 1mM CaCl ​2​, pH 6.8), 20 min. 
5. Wash 1x cold PBS. 
6. Block non-specific labeling in 2% BSA (in Triton-X 1:1000 in TBS), 10 min. 
7. Incubate in primary antibody solution, 60 min. 
a. Rabbit anti-Flag for Flag-AC9 
b. Mouse anti-HA for HA-B2AR 
8. Wash 1x cold PBS. 
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9. Incubate in secondary antibody solution, 20 min 
a. Donkey anti rabbit 488 for Flag AC9 
b. Donkey anti-mouse 647 for HA G(alpha)s 
10.Wash 1x cold PBS. 
11.Dip in water and aspirate, dry lightly on kimwipe (cell side up) and then fix 
onto slide with proLong gold anti fade mounting media (cell side down). 
 
Troubleshooting the transfection and fixation steps of the protocol 
We began by troubleshooting the protocol step by step. Our initial hypothesis was a 
technical issue with antibody staining. This is not uncommon in fixation experiments, 
especially when dealing with relatively small membrane structures like endosomes. 
However, our controls for antibody staining showed no improvement in the ability of 
others to reproduce the AC9 trafficking results, nor diminish my ability to consistently 
demonstrate isoproterenol-induced AC9 internalization. These early experiments were 
when we initially characterized as experiments being ‘negative’ or ‘positive’ for 
isoproterenol-induced AC9 trafficking (​Figure 3.1​).  
 
The next most likely factor was then the fixation step. It was typical for those of us who 
were focused on membrane trafficking at the endosome to fix cells in formaldehyde 
diluted in BRB80. This is an established buffer that has been described as promoting 
microtubule integrity, which can be useful for maintaining structure of the endosome 
membranes, particularly those with retromer (recycling) tubules. However, initial 
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experiments by others (Grace Peng, Mark von Zastrow) used formaldehyde diluted in 
PBS, which is sufficient for receptor fixation at the plasma membrane. We found that 
using 4% formaldehyde in BRB80 during the fixation step rather than in PBS greatly 
improved yield of AC9-positive endosomes (​Figure 3.2​). 
 
Although we established that the use of BRB80 over PBS was necessary to improve the 
consistency of ‘positive’ experiments, both in my hands and others, it did not eliminate 
the issues we had with consistency. Another area we were able to optimize in the 
fixation protocol was at the permeabilization step. Permeabilizing a cell membrane with 
detergent (0.1% Triton-X) in milk was the established protocol in our lab. We found that 
increased concentration of detergent helped with consistency, and we optimized the 
protocol with 0.2% Triton-X diluted in 2% Bovine Serum Albumin (BSA) in Tris-Buffered 
Saline (TBS) (​Figure 3.3​). While we saw incremental improvements in the quality of the 
images that could be captured with this optimized protocol, the consistency issue 
persisted. 
 
Timing of Transfection consistently affected AC9 internalization 
Having optimized the protocol post-fixation, we next asked whether there was a relevant 
factor while the cells were still live. Working backwards, we focused first on the 
transfection step. While transfection protocols are established by the manufacturer of 
transfection reagents, there is some inherent variation between subjects. We 
extensively troubleshot each step in the transfection protocols, to the point where two 
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subjects would do the same transfection side by side and would switch who did one 
step to isolate a particular step that might be the deciding factor.  
 
It was during this troubleshooting that we discovered the first consistent way to achieve 
consistent AC9 trafficking in someone else’s hands and block it in my hands. This 
experiment involved a side by side transfection in which subject A and subject B 
prepare transfection reagents for their own use and the other subject. Subject A would 
apply the transfection mix prepared by A to cells plated into two separate wells in a 
12-well plate (Plate 1). Subject A would then apply transfection mix prepared by B to 
two separate wells. Subject A would then place the Plate 1 in the incubator. Subject B 
would have done the same with transfection reagents prepared by B and A to a 
separate Plate 2. Once both plates were in the incubator, they were removed and A 
would take Plate 2, and B would take Plate 1. A would then use the reagents prepared 
by B and apply them to the two wells in the 12-well plate originally used by B (See Table 
1 for reference).  
 
What we found was that for the first time, ‘positive’ results for isoproterenol-induced 
AC9 trafficking correlated not with which subject performed the experiment, but 
surprisingly, who performed the transfection first on each plate (​Figure 3.4​). In the 
experiment described above, on both Plate 1 and 2, the person preparing the 
transfection reagent had no effect (​Figure 3.4​). All wells transfected by Subject A on 
Plate 1 were ‘positive’, while wells transfected by Subject B on Plate 1 were ‘negative’ 
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(​Figure 3.4​). Similarly, Subject B produced ‘positive’ results on Plate 2, and Subject A 
produced ‘negative’ results on Plate 2 (​Figure 3.4​). We concluded from this experiment, 
performed 5 separate times with consistent results, that the timing of the transfection 
was relevant. Although it wasn’t clear at the time, this was our first clue that the 
transfection reagents helped buffer an event that is triggered by taking the cells out of 
the incubator into a cell culture hood.  
 
Early experiments with AC9-EGFP stables 
Throughout this process, we were constantly trying to reduce the number of variables in 
the protocol. We eventually cloned AC9 from a Flag-tag vector into an EGFP vector. 
That plasmid was then transfected into HEK293 parental cells and maintained under 
selection until it AC9-EGFP was stably expressed in these cells. The motivation for 
developing this cell line as a tool was to eliminate the time consuming and resource 
intensive steps of transfection, permeabilization and antibody staining. Cells could be 
plated, stimulated, and fixed at low cost (both monetary and time), accelerating a 
lengthy protocol.  
 
Early validation of the stable AC9-EGFP cell line was initially confusing, though 
ultimately informative. In my hands, AC9 did not exhibit robust internalization with these 
cells at first (​Figure 3.5 (A)​). However, AC9 did internalize in these cells when the 
experiment was performed by another (Mark). This was a welcome but unexpected 
reversal of the typical dynamic. With the Subject A/B, Plate 1/2 experiment in mind, I 
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tested whether the transfection reagents were somehow able to buffer any negative 
effects of removing the cells from the incubator. I found that transfecting these stable 
cell lines with empty pcDNA3 vector seemed to improve things in my hands (​Figure 3.5 
(B)​). I also transfected these stable cells with Flag-AC9 and observed colocalization of 
the Flag-tagged construct and the EGFP-tagged construct, although the stably 
expressed AC9-EGFP exhibited higher expression (​Figure 3.5 (C)​). 
 
Even more unexpected, this changed back to the original dynamic after a few 
experiments, in which the stable cells were positive for AC9 internalization in my hands 
but not in Marks. However, we found that if I split my cells into two flasks and gave one 
to Mark, the first experiment he would perform with those would be positive. 
Subsequent experiments with Mark passaging the cells in between experiments were 
negative. This led to our hypothesis that it was the way that I passaged my cells that 
was maintaining the cells in a state that promoted trafficking. A third party (Kyra) made 
the outside observation that the timing of my cell passaging / plating of cells onto 
coverslips was much faster than others (Mark). Based on this, we asked whether this 
was a relevant factor to AC9 internalization.  
 
Updated protocol 
Day 0: Plate AC9-EGFP stable cell line (HEK293) 
1. Flame coverslips and place each one in a separate well. 
2. Coat coverslips with 0.1% Poly-L Lysine in deionized water for 15 minutes. 
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3. Aspirate and let dry for 15 minutes. 
4. Wash 3X with deionized water and let dry for 15 minutes.  
5. Remove flask from incubator and aspirate. 
6. Wash cells in flask with 3mL PBS-EDTA. 
7. Apply 1mL PBS-EDTA to cells in flask and incubate 3 minutes. 
8. Resuspend cells in 9mL DMEM (+10% FBS). 
9. Plate cells onto coverslips. 
Day 2: Fix cells. 
1. Stimulate for 30 min with 10uM isoproterenol. 
2. Wash 1x cold PBS. 
3. Fix cells with 4% formaldehyde in modified BRB80 buffer (80mM PIPES, 
1mM MgCl​2​, 1mM CaCl ​2​, pH 6.8), 20 min. 
4. Wash 1x cold PBS. 
5. Dip in water and aspirate, dry lightly on kimwipe (cell side up) and then fix 
onto slide with proLong gold anti fade mounting media (cell side down). 
 
Stables that never leave the incubator 
Throughout the (now simplified) experiment, typically one would take the cells out of the 
incubator briefly to check confluency, exchange media to promote growth, and in 
general monitor the health of the cells through a light microscope. With the idea that 
taking cells out of the incubator could be a factor as well as the timing of execution of 
the protocol, we asked whether these normal observations could actually be a 
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Shroedinger’s cat scenario in which observation of the cells was disrupting them. 
Consistent with this, we found that never removing the cells from the incubator seemed 
to improve things (​Figure 3.6 (A)​) both in my hands and others (Mark). 
 
0, 1, 2, 3 minutes out of the incubator 
Now armed with the more concrete hypothesis that removing cells from the incubator 
could be a relevant factor, we attempted to determine the parameters of the 
phenomenon. Cells were placed in separate 12-well plates and incubated for 24 hours. 
Each plate was then removed from the incubator and placed in a normal cell culture 
hood for 1, 2, or 3 min (an additional plate never left the incubator) before being 
returned to the same incubator. As seen in confocal optical sections images in (​Figure 
3.6 (B)​), 3 minutes out of the incubator appeared to block isoproterenol-induced AC9 
trafficking in these AC9-EGFP stable HEK293 cells.  
 
We quantified this across 10 fields per condition, over 3 experiments. Each field had at 
least 20 cells. Two methods of quantification were used: counting the number of internal 
puncta per cell (​Figure 3.6 (C)​), and then the percent cells per field that were ‘positive’, 
that is, they had more than 10 endosomes (​Figure 3.6 (D)​). The former was a raw 
metric demonstrating AC9 internalization. The latter is a more qualitative metric that 
attempts to demonstrate that when an experiment is ‘positive’, almost all the cells 
present this phenotype; it’s not a matter of picking and choosing desirable cells. 
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Notably, 2 minutes out of the incubator seemed to reduce AC9 internalization marginally 
in this cell line, but cells still averaged greater than 10 endosomes, qualifying them as 
‘positive’ for AC9 trafficking. But 3 minutes out of the incubator dramatically reduced 
AC9 internalization (​Figure 3.6 (C)​). A window of 1 minute between the 2 and 3 minute 
time points was then established, perhaps unprecedented in biology.  
 
CO2 incubator, Hepes, Optimem 
We speculated several causes behind this novel phenomenon in which cells that were 
removed from the incubator and then replaced after 2 minutes, but not 3 minutes, 
presented an isoproterenol-induced AC9 trafficking phenotype. Chief amongst these 
were: 1. Temperature gradient, 2. pH gradient, and 3. CO2 gradient, since temperature, 
humidity and CO2 are controlled by the incubator, and pH gradients have been a noted 
source of cell distress before. Initial experiments with pH control by the addition of 
Hepes during the 3 min room air challenge showed little effect, but treatment with the 
transfection reagent Opti-MEM did (​Figure 3.7 (A)​). 
 
However, CO2 gradients proved a fruitful direction. The gauge for the CO2 source to a 
separate incubator was locked so that the incubator was not able to supplement the 
levels of CO2 at room air. We referred to this as a CO2 negative (-CO2) environment, 
although of course it was at room levels. But this allowed a controlled system to 
compare incubation with elevated CO2 and without. Cells were either left in the normal 
incubator or removed and placed in the -CO2 incubator before being returned to the 
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normal incubator after 3 minutes. We found that this was sufficient to block 
isoproterenol-induced AC9 trafficking in wide-field epifluorescence images (​Figure 3.7 
(D)​). Quantification of the endosomes per cell and positive cells per field supported 
these observations (​Figure 3.7 (E, F)​). 
 
Application of the pH buffer Hepes or the transfection reagent Opti-MEM increased the 
number of endosomes per cell (​Figure 3.7 (D, E)​). Only Opti-MEM produced AC9 
trafficking that qualified as ‘positive’ by our metric of more than 10 endosomes per cell 
on average (​Figure 3.7 (D, F)​). However, this was not a full recovery of the effect. This 
investigation is currently ongoing and we are (and will be) characterizing this further. 
 
5 day cycle 
One way we have characterized this phenomenon is recovery over long time periods. 
Cells were grown on coverslips in separate 12-well plates. These plates were removed 
for 3 minutes to room air (cell culture hood) before being returned to a normal incubator. 
Cells were then incubated for various lengths of time: 12, 24, 36, 48, 72, 96, and 120 
hours. After this long term incubation, cells were stimulated with isoproterenol and then 
fixed as per the updated protocol. Cells were imaged by wide field epifluorescence 
microscopy and quantification of AC9 internalization was performed as described 
above. We found that AC9 trafficking exhibited a local minimum after 48 hours of 
incubation and slowly recovered after another 72 hours, for a total of 120 hours (​Figure 
3.8​).  
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3.4 Discussion 
Our data suggests that AC9 trafficking is controlled by a regulatory mechanism that is 
sensitive to a relatively acute event. Three minutes exposure to a negative CO2 
gradient is sufficient to inhibit isoproterenol-induced AC9 internalization over a five day 
period. This is not true for the B2AR, and we have already described other fundamental 
differences in the regulatory mechanisms governing AC9 and B2AR trafficking from the 
plasma membrane to the endosome in Chapter 2. Here we begin to characterize this 
unprecedented sensitivity to removal from the incubator for a short period of time, which 
produces an effect that lasts for up to 120 hours.  
 
This is a remarkable discovery in HEK293 cells, which rapidly grow and double every 
12-24 hours on average. Inhibition of AC9 trafficking over several generations of cell 
division suggests genetic expression changes. We interpret this data as either the 
increase in expression of an inhibitory factor in response to the negative CO2 gradient 
presented by room air relative to the incubator, or the rapid degradation of a necessary 
component of the AC9 trafficking regulatory mechanism and slow recovery of 
expression over several days. RNAseq experiments are the obvious next step, with an 
option for mass spectrometry as well. AC9 expression appeared fairly stable across 
conditions and replicates in this experiment, but we did not control for proteolysis or 
continued expression of AC9.  
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This also provides us with the first consistent method to block AC9 endocytosis in 
conditions that B2AR endocytosis is unaffected. We have previously shown that AC9 
can internalize in a receptor-independent manner due to Gs activation. This will allow us 
to test the cAMP response in cells that are under conditions which inhibit the trafficking 
of B2AR, AC9, or both. The unique properties of AC9 are of note: it’s high basal activity, 
autoinhibitory domain, and requisite of high concentrations of Gs. AC9 might not require 
an upstream GPCR at the endosome to contribute to functionally relevant signaling. 
Further exploration into the trafficking determinants of AC9 and the signaling 
implications are currently active areas of investigation in the lab. 
 
As of the writing of this thesis, we now have a better understanding of the situation. 
More specifically, we found that a negative CO2 gradient can inhibit AC9 trafficking 
within 3 minutes. This is less of an explanation and more of a first clue. Standard 
protocol for plating cells involves counting the cells so that they can be plated at a 
certain concentration (‘confluence’) for consistent results. Our results indicate that this 
can block AC9 trafficking if it takes longer than 3 minutes, which it usually does. This 
could potentially mean that a lot of experiments that involve cell culture might not be 
properly controlled. An investigation of exactly what causes this and the implications on 
cell biology has begun and will continue after my time in the lab. It is possible that some 
or all of this story will be written up in a paper or submitted in some form to bioRxiv, but 
at the very least it will be recorded here. The clue that we have now is exciting in its 
absolutely unprecedented nature and its wide implications on cell culture. 
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As far as we can tell through extensive discussion with others in the field (and across 
fields in UCSF generally), this is a completely novel phenomenon. While fascinating, it 
is still poorly characterized. More work is necessary to better understand this sensitivity 
to CO2 gradient. Other cellular responses to stress such as temperature ​(Underhill and 
Smales 2007)​, ionic distress, and even oxygen ​(Ast and Mootha 2019)​ have been noted 
with varying levels of understanding. However, while control of CO2 concentration in 
incubators is known to be necessary for homeostasis, the acute nature of the 
phenomenon described here and its long term effects are unprecedented. 
 
This has been a baffling project thus far and it took years of painstaking troubleshooting 
to get to even this first clue. Despite the difficulty in even defining the parameters 
involved, we are motivated to continue investigating this unknown system. AC9 is 
known to be a B2AR effector in human airway smooth muscle tissue including the throat 
and lungs. We speculate that AC9 trafficking’s CO2 sensitivity has biological and clinical 
relevance in this context, but as of now the phenomenon is still poorly defined. 
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3.6 Materials & Methods 
Cell Culture + Constructs 
HEK 293 cells (ATCC) were cultured in complete growth Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco) and supplemented with 10% fetal bovine serum (UCSF Cell 
Culture Facility). We note that AC9 most consistently internalized in cells that were not 
removed from the incubator for longer than 3 min during plating or transfection. 
HA-β2AR ​(Tang et al. 1999; von Zastrow and Kobilka 1992)​ described previously, was 
sub-cloned from Flag-tagged constructs. Transfections were carried out using 
Lipofectamine 2000 (Life Technologies) according to the manufacturer’s protocol. Cells 
were transfected 48 hours before experiments.  
 
Antibodies 
Primary antibodies used were rabbit anti-Flag (Sigma), mouse anti-Flag M1 (Sigma), 
mouse anti-Flag M2 (Sigma), mouse anti-HA 16B12 (Biolegend), rat anti-HA (Roche). 
 
Fixed cell confocal imaging 
Cells were transfected with the indicated construct(s) and then plated on glass 
coverslips coated with poly-L-lysine (​0.0001%, ​Sigma) 24 hours later. For antibody 
feeding assays, cells were: (1) placed on ice and rinsed with ice-cold 
phosphate-buffered saline (PBS), (2) labeled by the addition of antibodies diluted 
1:1000 in DMEM for 10 minutes, and (3) rinsed with room temperature PBS and allowed 
to traffic for 30 minutes by the addition of 37​°​C​ ​fresh media (DMEM + 10% fetal bovine 
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serum) with or without a saturating concentration of β2AR agonist (10 ​μ​M isoproterenol, 
Sigma), V2R agonist (10 µM arginine-vasopressin, Sigma), MOR agonist (10 µM 
DAMGO, Sigma), or forskolin (10 µM, Sigma). For all assays, cells were rinsed with cold 
PBS and fixed by incubation in 3.7% formaldehyde (Fisher Scientific) diluted in modified 
BRB80 buffer (80mM PIPES, 1mM MgCl​2​, 1mM CaCl​2​, pH 6.8) for 20 minutes at room 
temperature. Cells were then blocked in 2% Bovine Serum Albumin (Sigma) in PBS with 
permeabilization by 0.2% triton X-100 (Sigma). Primary antibody labeling was 
performed by the addition of antibodies diluted 1:1000 in blocking/ permeabilization 
buffer for one hour at room temperature. Secondary labeling was performed by the 
addition of the following antibodies diluted at 1:500 in blocking/ permeabilization buffer 
for 20 minutes at room temperature: Alexa Fluor 555 or 488 donkey anti-mouse 
(Invitrogen), Alexa Fluor 555 or 488 donkey anti-rabbit (Invitrogen), Alexa Fluor 488 or 
555 goat anti-rat (Invitrogen), or Alexa Fluor 488 donkey anti-sheep (Life Technologies). 
Specimens were mounted using ProLong Gold antifade reagent (Life Technologies). 
 
Fixed cells were imaged by spinning disc confocal microscope (Nikon TE-2000 with 
Yokogawa confocal scanner unit CSU22) using a 100X NA 1.45 objective.​ A 488 nm 
argon laser and a 568 nm argon/krypton laser (Melles Griot) were used as light 
sources. 
 
Statistical Analysis 
Results are displayed as mean of results from each experiment or data set, as indicated 
in Figureure legends. The statistical significance between conditions for experiments 
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with two conditions was calculated using paired, two tailed t-tests. ​All statistical 
calculations were performed using Excel (Microsoft Office) or Prism (GraphPad). The 
threshold for significance was p<0.05 and the coding for significance is reported as 
follows: (n.s.) p>0.05, (*) p≤0.05, (**) p≤0.01. 
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3.8 Figures
 
Figure 3.1: AC9 trafficking is consistent within an experiment but not across 
subjects. 
(A)​ Representative epifluorescence imaging of HEK293 cells coexpressing HA-B2AR 
and Flag-AC9 that were treated with 10 µM isoproterenol for 30 min. Scale Bar is 8 µm. 
(B)​ Quantification of internal puncta that are β2AR or AC9 positive, taken from wide field 
images (A) [mean±SEM; n=3 experiments, 10 visual fields and 200+ cells per 
condition]. ** P < 0.01 by two-tailed t-test.  
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Figure 3.2: BRB80 improves fixation of Flag-AC9 in HEK293 cells.  
(A)​ Representative epifluorescence imaging of HEK293 cells expressing Flag-AC9 that 
were treated with 10 µM isoproterenol or control for 30 min and fixed with formaldehyde 
in BRB80 or PBS. Scale Bar is 8 µm. ​(B)​ Quantification of internal puncta that are AC9 
positive, taken from wide field images (A) [mean±SEM; n=3 experiments, 10 visual 
fields and 200+ cells per condition]. ** P < 0.01 by two-tailed t-test. 
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Figure 3.3: 0.2% Triton-X in 2% BSA-TBS  improves fixation of Flag-AC9 in 
HEK293 cells.  
 
(A)​ Representative epifluorescence imaging of HEK293 cells expressing Flag-AC9 that 
were treated with 10 µM isoproterenol or control for 30 min and permeabilized with 0.1% 
Triton-X in 2% milk (TBS) or 0.2% Triton-X in 2% BSA (TBS). Scale Bar is 8 µm. ​(B) 
Quantification of internal puncta that are AC9 positive, taken from wide field images (A) 
[mean±SEM; n=3 experiments, 10 visual fields and 200+ cells per condition]. ** P < 0.01 
by two-tailed t-test. 
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Figure 3.4: Timing of transfection is relevant to AC9 trafficking.  
Representative epifluorescence imaging of HEK293 cells expressing Flag-AC9 that 
were treated with 10 µM isoproterenol for 30 min. Cells in Plate 1 were transfected by 
AL first and MvZ second, with reagents prepared by AL or MvZ as indicated. Plate 2 
was transfected by MvZ first and AL second. Scale Bar is 8 µm.  
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Figure 3.5: Initial testing of the AC9-EGFP stable cell line.  
(A)​ Representative confocal imaging of AC9-EGFP stable HEK293 cells that were 
treated with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 µm. ​(B) 
Representative confocal imaging of AC9-EGFP stable HEK293 cells transfected with 
vehicle or pcDNA3 vector were treated with 10 µM isoproterenol or control for 30 min. 
Scale Bar is 8 µm. ​(C)​ Representative confocal imaging of AC9-EGFP stable HEK293 
cells transfected with Flag-AC9 were treated with 10 µM isoproterenol or control for 30 
min. Scale Bar is 8 µm. 
120 
 Figure 3.6: Removal from incubator for 3 minutes inhibits AC9 trafficking in 
AC9-EGFP stable cells. 
(A)​ Representative confocal imaging of AC9-EGFP stable HEK293 cells which never 
left the incubator were treated with 10 µM isoproterenol or control for 30 min. Scale Bar 
is 8 µm. ​(B)​ Representative confocal imaging of AC9-EGFP stable HEK293 cells were 
treated with 10 µM isoproterenol for 30 min. Cells were removed from the incubator to a 
cell culture hood for 0, 1, 2, or 3 minutes and then returned to the incubator 48 hours 
before stimulation. Scale Bar is 8 µm.​ (C) ​Quantification of internal puncta that are AC9 
positive, taken from wide field images (B) [mean±SEM; n=3 experiments, 10 visual 
fields and 200+ cells per condition]. ** P < 0.01 by two-tailed t-test. ​(D)​ Quantification of 
cells with >10 internal puncta that are AC9 positive, taken from wide field images (B) 
[mean±SEM; n=3 experiments, 10 visual fields and 200+ cells per condition]. ** P < 0.01 
by two-tailed t-test. 
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Figure 3.7: A negative CO2 gradient is sufficient to inhibit AC9 trafficking. 
(A)​ Representative confocal imaging of AC9-EGFP stable HEK293 cells removed from 
the incubator for 0 or 3 minutes and Opti-MEM or control (48 hours prior) were treated 
with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 µm. ​(C)​ Quantification of 
internal puncta that are AC9 positive, taken from wide field images (A) [mean±SEM; n=3 
experiments, 10 visual fields and 200+ cells per condition]. ** P < 0.01 by two-tailed 
t-test. ​(C)​ Quantification of cells with >10 internal puncta that are AC9 positive, taken 
from wide field images (A) [mean±SEM; n=3 experiments, 10 visual fields and 200+ 
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cells per condition]. ** P < 0.01 by two-tailed t-test. ​(D)​ Representative confocal imaging 
of AC9-EGFP stable HEK293 cells removed from a normal incubator to a CO2- 
incubator 3 minutes and treated with control, 10mM Hepes, or Opti-MEM (48 hours 
prior) were treated with 10 µM isoproterenol for 30 min. Scale Bar is 8 µm. ​(E) 
Quantification of internal puncta that are AC9 positive, taken from wide field images (A) 
[mean±SEM; n=3 experiments, 10 visual fields and 200+ cells per condition]. ** P < 0.01 
by two-tailed t-test. ​(F)​ Quantification of cells with >10 internal puncta that are AC9 
positive, taken from wide field images (A) [mean±SEM; n=3 experiments, 10 visual 
fields and 200+ cells per condition]. ** P < 0.01 by two-tailed t-test.  
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Figure 3.8: Acute exposure to room air inhibits AC9 for 5 days. 
(A)​ Representative confocal imaging of AC9-EGFP stable HEK293 cells removed from 
the incubator for 3 minutes were incubated for 12, 24, 336, 48, 72, 96 or 120 hours 
before treatment with 10 µM isoproterenol for 30 min. Scale Bar is 8 µm. ​(C) 
Quantification of internal puncta that are AC9 positive, taken from wide field images (A) 
[mean±SEM; n=3 experiments, 10 visual fields and 200+ cells per condition]. ** P < 0.01 
by two-tailed t-test. ​(C)​ Quantification of cells with >10 internal puncta that are AC9 
positive, taken from wide field images (A) [mean±SEM; n=3 experiments, 10 visual 
fields and 200+ cells per condition]. ** P < 0.01 by two-tailed t-test.  
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Chapter 4: 
 
Discussion 
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4.1 Dynamic trafficking of a Gs effector to the endosome  
The early model of GPCR-mediated signaling and regulation by membrane trafficking 
emerged before a more complex understanding of the cell could provide necessary 
context. It was not unreasonable at the time to explain the observed cycle of 
desensitization and resensitization as membrane trafficking of the receptor from the 
plasma membrane to the endosome and back. Early biochemical testing indicated that 
receptor phosphorylation and internalization was coincident with an arrest of the initial 
acute cAMP response in the cell. Given the fairly small distances involved in the cell 
types used, it was reasonable that the system could rely on the fast diffusion of a large 
cAMP gradient from the plasma membrane to various effectors throughout the cell.  
 
As an increasingly large number of GPCRs were catalogued, it became clear that cAMP 
alone is not enough for effector specificity. AKAPs scaffolding of AC isoforms and 
effectors allows a system that funnels several signal pathways through a single 
molecule to achieve input-output specificity. This growing understanding of local cAMP 
signaling as a proximally coordinated process is part of the logical foundation for 
endosome-based signaling. Studies of GPCR-mediated signaling in larger cell types 
such as neurons provided the first indication that delivery by the endocytic network may 
actually be required for the transmission of certain signals. Endosomal signaling is a 
necessity in cells in which it is energetically inefficient to rely on the diffusion of a small 
molecule gradient.  
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With several studies suggesting that the endosome is the site of GPCR and G protein 
activation, a critical question emerged: is there a Gs-regulated effector at the 
endosome? The data provided in this thesis demonstrate that AC9 is one such effector. 
We also show that this process is isoform specific, as AC1 remained restricted to the 
plasma membrane under all conditions tested in the same cells. However, we do not 
claim that AC9 is the only endosome-associated isoform. Given evidence suggesting 
AC2’s involvement in PTHR signaling ​(Ferrandon et al. 2009)​ and AC5/6 association 
with AKAP79/150 (the only AKAP known thus far to enter endosomes) ​(Keith et al. 
2012)​, we deem it likely that AC9 is not unique in this way. Rather, our observation of 
endosome-localized AC9 probably represents merely the first of many observations of 
differential AC localization.  As AC isoform regulation includes cell type expression and 
co-expression with relevant AKAPs, a comprehensive model may take extensive 
exploration of relevant AC isoform localization in a variety of cell lines. However, we 
acknowledge that studies of AC localization have historically be hindered by a lack of 
good antibodies, low endogenous expression, and difficulty in cloning these very large 
proteins. 
 
We also showed that not only is AC9 present at the endosome, but that it undergoes 
dynamically regulated endocytosis from the plasma membrane as a result of upstream 
Gs-coupled receptor activation. More specifically, activation of Gs and its engagement 
with AC9 is necessary and sufficient to drive AC9 internalization. This has several 
implications, the first being that adenylyl cyclases can exhibit isoform-specific trafficking. 
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This suggests that the endocytic network is not limited to just to deliver receptor and G 
protein to effectors around the cell (possibly coordinated by AKAPs). Rather, the 
endosome can constitute and deliver a complete GPCR-mediated signaling cascade 
with spatial and effector specificity.  
 
The endosome is increasingly understood to be the site of GPCR-mediated signaling 
rather than the pool of inactive receptors. The existence of a Gs-regulated effector at 
the endosome is a significant step forward in the evolving model of the endosome. The 
revelation that the endocytic network differentially regulates AC isoforms and receptors 
and coordinates the necessary components for a cAMP response is massive. An 
overreliance on the assumption that cAMP diffusion is sufficient for robust Gs-regulated 
signal transduction must be challenged. Instead, a model in which the endocytic 
network and scaffolding proteins such as AKAPs are key spatial regulators of local 
cAMP signaling can be favored.  
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4.2 Distinct regulatory mechanism of AC9 trafficking 
Data presented in this thesis strongly indicates that AC9 trafficking is regulated by a 
mechanism that is distinct from the B2AR. This was demonstrated in several ways in 
Chapter 2: genetic inhibition of receptor internalization (endocytic mutant V2R-T) did not 
affect AC9 trafficking, genetic and chemical activation of Gs was sufficient to drive AC9 
internalization (but not B2AR), and arrestin knockout blocked receptor trafficking but 
had no effect on AC9. The acute negative CO2 gradient described in Chapter 3 was 
also shown to inhibit trafficking of AC9 but not B2AR. All of these data would be 
inconsistent with a model in which AC9 internalizes as a consequence of receptor 
endocytosis, either by tethering in a physical complex or by bulk membrane flow. 
Rather, they support a model in which AC9 localization is dynamically regulated, in 
which Gs plays a key role both in promoting catalytic activity and in accumulation in 
early endosomes.  
 
While it is clear that B2AR and AC9 are regulated by distinct mechanisms, both proteins 
undergo regulated endocytosis from the plasma membrane to the endosome as a result 
of ligand binding of the receptor. Further studies into the relative kinetics of these 
processes are an immediate priority to the von Zastrow lab. Whether AC9 also enters 
clathrin coated pits and what, if any, adaptor proteins are involved in the accumulation 
of AC9 in B2AR-containing CCPs, is also of great interest. A comparison across GPCRs 
is also appropriate. Class B receptors such as the V2R and PTHR have been described 
in a ‘megaplex’ ​(Thomsen et al. 2016)​ with G protein and arrestin. The B2AR is a class 
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A GPCR, which does not associate in a stable complex with arrestin at the endosome. 
A comparison of long-term GPCR cargo sorting and AC isoform trafficking should prove 
informative. What role arrestin has in scaffolding or inhibiting GPCR-mediated cAMP 
response generated at the endosome will be an important question in the field.  
 
One of the primary reasons we investigated AC9 membrane trafficking was that it was 
shown to be depleted from the plasma membrane due to retromer knockdown 
(Steinberg et al. 2013)​. We hypothesize that AC9 can undergo retromer-dependent 
recycling back to the plasma membrane, although this may be cell line specific. 
Although not formally presented in this thesis, we have observed AC9 and Gs in tubules 
extending from the endosome. Whether these tubules are retromer (recycling) tubules 
or not has not yet been rigorously investigated. Identification of a retromer-binding motif 
on AC9 or some binding partner, and observation of B2AR, Gs, and AC9 cargo sorting 
into retromer tubules, are active areas of interest in the von Zastrow lab.  
 
The role of Gs in both promoting AC activity and in membrane trafficking of AC9 is a 
rather surprising one. We hypothesize that while Gs activation is both necessary and 
sufficient for AC9 trafficking, other binding partners such as AKAPs are more intimately 
involved in the membrane trafficking decisions. AC9 is most commonly associated with 
the plasma membrane localized AKAP, Yotiao. Yotiao is critical for coordination of 
adrenergic receptor signaling through AC9 with potassium channels in cardiac tissue ​(Li 
et al. 2012)​, but its role and localization patterns are not well described in other cell 
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lines. It is possible that Yotiao is involved in the accumulation of AC9 in endocytic pits, 
or that AC9 dynamically associates with another AKAP during this process. AC9 has not 
been previously associated with the only known AKAP to enter endosomes, 
AKAP79/150 ​(Keith et al. 2012)​. However, AC5 and AC6 have both been associated 
with AKAP79/150. It is possible that AC9 heterodimerization with AC5/6 ​(Baldwin et al. 
2019)​ is required for AKAP79/150-dependent recruitment to the endosome. It is also 
possible that AC9 does not require engagement with an AKAP to enter endosomes. It 
has been proposed that GPCR endocytosis promotes a sustained cAMP response in 
part through separation from plasma membrane associated PDEs ​(Tsvetanova and von 
Zastrow 2014)​, and it is possible that AC9 has a similar relationship with Yotiao. 
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4.3 AC9 activity at the endosome 
We also presented data in Chapter 2 that demonstrated that AC9 is a major contributor 
to the B2AR-mediated cAMP response from the endosome in HEK293 cells. 
Comparison of the antagonistic effects of the membrane permeant alprenolol and 
membrane impermeant CGP12177 enabled the isolation of a B2AR-mediated signal 
from an internal compartment. The CGP-insensitive ‘signal gap’ was shown to be 
eliminated by AC9 knockdown and by endocytic blockade with the dynamin inhibitor 
DYNGO-4a. Overexpression of AC9 (but not AC1) in AC3/6 double knockout cells was 
sufficient to produce a detectable CGP-insensitive cAMP response. These data were all 
consistent with the idea that B2AR mediates a cAMP response from the endosome, 
which is amplified in large part by AC9 in HEK293 cells.  
 
AC9 activity has several unique characteristics relative to the other AC isoforms, 
including insensitivity to activation by forskolin, as well as insensitivity to direct inhibition 
by Protein Kinase A, Protein Kinase C, Gᵦᵧ, and Gi ​(Baldwin et al. 2019)​. AC9 has also 
been described to have a relatively high basal activity and requires higher concentration 
of Gs for maximal activity ​(Baldwin et al. 2019)​, but is unique amongst AC isoforms in 
that it has an autoinhibitory domain in its C terminus ​(Pálvölgyi et al. 2018)​. It is possible 
that once AC9 undergoes regulated endocytosis from the plasma membrane, it does 
not require receptor or even Gs engagement to continue propagating a cAMP response 
from the endosome.  
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Our data suggests that AC9 is the major contributor to the B2AR-mediated cAMP 
response from endosomes. However, this does not preclude other AC isoform 
involvement at the endosome. As mentioned previously, B2AR is a class A GPCR 
which is rapidly dephosphorylated at the endosome leading to arrestin dissociation. 
However, Class B receptors like the V2R continue to associate with arrestin and even 
form a supercomplex with Gs as well. It is probable that GPCR identity and its 
consequential binding partners (including AKAPs) may be a determinant for which AC 
isoform is active in a cell at any given time. Comparison of endosomal signaling across 
GPCRs and with disruption of arrestin binding is an active area of investigation in the 
von Zastrow lab.  
 
A thorough investigation of how AC isoform localization affects the overall cellular 
response is necessary. It has been shown that the location of cAMP production affects 
responses in genetic expression ​(Tsvetanova and von Zastrow 2014)​. It has also been 
shown that AKAP localization and association with specific AC isoforms is important in 
several cell types ​(Keith et al. 2012; Esseltine and Scott 2013; Delint-Ramirez et al. 
2015; Gros et al. 2006; Dessauer 2009)​. Isoform-specific membrane trafficking through 
the endocytic network is a significant puzzle piece in the growing understanding of 
spatial and effector specificity of cAMP signaling. 
 
  
133 
4.4 Inconsistency (a theme with AC9) 
Cell signaling is notoriously difficult to study due to inconsistency and noise in data, and 
AC9 is a perfect example of this. Initial cloning of AC9 produced constructs of different 
length ​(Hacker et al. 1998; Iourgenko et al. 1997)​. Originally described as sensitive to 
inhibition by calmodulin and PKC but not Gᵦᵧ or Gi ​(Dessauer et al. 2017)​, recent 
studies ​in vitro​ indicate that AC9 is not directly regulated by any of these mechanisms 
(Baldwin et al. 2019)​. However, heterodimerization with AC5/6 ​(Baldwin et al. 2019) 
may result in indirect regulation by some of these molecules and may explain the 
inconsistent reports of AC9 regulation.  
 
Furthering this previously noted inconsistency in the literature is the subject of AC9 
trafficking as discussed in Chapter 3. We devoted almost 3 years to troubleshooting the 
fixation protocol and ultimately discovered that AC9 trafficking is sensitive to inhibition 
by an acute exposure to a negative CO2 gradient. Other groups (including unpublished 
work) have noticed similar issues with standard cell culture techniques, describing 
sensitivity to temperature and oxygen gradient ​(Ast and Mootha 2019)​. It is not 
unreasonable that cells can quickly detect changes in their environment, but this 
appears to have been greatly underestimated by the cell biology field as a whole. The 
importance of cAMP signaling on physiological responses and drug development may 
force the scientific community to address these sensitivities. A wide array of cellular 
responses have been affected by any number of these phenomena unbeknownst to the 
researchers performing the assays.  
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